[go: up one dir, main page]

AU2005206307A1 - Aryl substituted heterocycles, method for production and use thereof as medicaments - Google Patents

Aryl substituted heterocycles, method for production and use thereof as medicaments Download PDF

Info

Publication number
AU2005206307A1
AU2005206307A1 AU2005206307A AU2005206307A AU2005206307A1 AU 2005206307 A1 AU2005206307 A1 AU 2005206307A1 AU 2005206307 A AU2005206307 A AU 2005206307A AU 2005206307 A AU2005206307 A AU 2005206307A AU 2005206307 A1 AU2005206307 A1 AU 2005206307A1
Authority
AU
Australia
Prior art keywords
alkyl
independently
another
group
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005206307A
Inventor
Thomas Boehme
Matthias Gossel
Gerhard Hessler
Lothar Schwink
Petra Stahl
Siegfried Stengelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2005206307A1 publication Critical patent/AU2005206307A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

IN THE MATTER of a PCT Application in the name of Sanofi-Aventis Deutschland GmbH filed under PCT/EP2005/000699 and IN THE MATTER of its transfer for an Application for an Australian Patent I, Gunter lsenbruck, Dr. rer.nat., Dipl.Chem., Patentanwalt and European Patent Attorney in Mannheim (F.R.G.), do solemnly and sincerely declare that I am conversant with the English and German languages and am competent in translating thereof, and that the following is, to the best of my knowledge and belief, a true and correct translation of the International Patent Application filed under No. PCT/EP2005/000699 by Sanofi-Aventis Deutschland GmbH for ,,Aryi-substituted heterocycles, method for production and thereof as medicaments" Mannheim, July 13, 2006 D Gunter Isenbruck AS ORIGINALLY FILED Aryl-substituted heterocycles, method for production and thereof as medicaments 5 The invention relates to aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. 10 Compounds similar in their overall structure to the heterocycles described herein and having a pharmacological effect have been described in the prior art. Thus, for example, WO 03/097047 describes aryl-substituted oxadiazoles for the treatment of obesity and diabetes. Compounds with MCH-antagonistic activity for treatment of obesity are disclosed in the 15 prior art (examples: W02001021577, W02003035624, W02002089729, W02002006245, W02002002744, W02002057233, W02003045313, W02003097047, W02002010146, W02003087044). The invention was based on the object of providing compounds which bring about a weight 20 reduction in mammals and are suitable for the prevention and treatment of obesity and diabetes. Surprisingly, a series of compounds which modulate the activity of MCH receptors has been found. In particular, the compounds are distinguished by MCH I R antagonism. 25 The invention therefore relates to compounds of the formula I, R7 R6 R11'K E\ X-Het/ N " NRR2 G-D m R4 R9 R8 R5 in which the meanings are 2 RI, R2 independently of one another H, (CI-Cs)-alkyl, -(CRI3RI4)o-R12, (C 1
-C
4
)
alkoxy-(CI-C4)-alkyl, (C 3
-C
8 )-alkenyl, (C 3
-C
8 )-alkynyl, CO-(CI-Cs)-alkyl, CO-(CH 2 )o-R 12, CO(C(R I 5)(R 16))qN(R 17)(R 18), CO(C(Rl9)(R20)),O(R2l); or RI and R2 form together with the nitrogen 5 atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C)-alkyl, 0-(CI-Cs)-alkyl, (CI-C 4 )-alkoxy 10 (CI-C 4 )-alkyl, hydroxy-(CI-C 4 )-alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(Ci-C 6 )-alkyl, N(R27)(R28) or SO 2
CH
3 ; o 0, 1,2,3,4,5,6; 15 q,s independently of one another 0, 1, 2, 3, 4; R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (Ci-C 6 )-alkyl; 20 R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N 25 (Ci-C)-alkyl, oxygen and sulfur; R 12 OH, O-(C 1
-C
6 )-alkyl, CN, COO(R29), CON(R30)(R3 1), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may 30 comprise further substituents such as F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O-(CI-C 6 )-alkyl, (CI-C 4 )-alkoxy-(Ci-C 4 )-alkyl, S-(CI-C 6 )-alkyl, (CI C)-alkyl, (C 2 -C)-alkenyl, (C 3 -Cs)-cycloalkyl, (C 2
-C
6 )-alkynyl, 0-(Co-C 8
)-
3 alkylene-aryl, (Co-Cs)-alkylene-aryl, N(R34)(R35), CO(Cr-C 6 )-alkyl, COO(R36) and S(O), (R37); u 0, 1, 2; 5 R34, R35 independently of one another H, (CI-Cs)-alkyl; R34 and R35 10 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 )-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups; 15 R36, R37 H, (CICs)-alkyl; R13, R14 independently of one another H, (CI-Cs)-alkyl, hydroxy-(C 1
-C
4 )-alkyl, OH, (Cr-C 4 )-alkoxy-(CI-C 4 )-alkyl; 20 R29, R30, R31 independently of one another H, (Ci-Cs)-alkyl, (C 2
-C
6 )-alkenyl, (CO-C 8
)
alkylene-aryl; R32, R33 independently of one another H, (C-C 6 )-alkyl 25 or R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and 30 sulfur and optionally be substituted by 1-2 oxo groups; R3 H, (C-C 6 )-alkyl; 4 R4, R5 independently of one another H, (CI-C 6 )-alkyl, OH, O-(Ci-C 6 )-alkyl, 0 CO(Ci-C 6 )-alkyl, S-(CI-C 6 )-alkyl; R6, R7, R8, R9 5 independently of one another H, (CI-Cs)-alkyl, or R6 and R7, R8 and R9 independently of one another optionally oxo; 10 n, m independently of one another 0, 1, 2; A, B, D, G independently of one another N, C(R38); R38 H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O-(CI-C 6 )-alkyl, 0-(CI-C 4
)
15 alkoxy-(CI-C 4 )-alkyl, S-(CI-C 6 )-alkyl, (CI-C 6 )-alkyl, (C 2
-C
6 )-alkenyl, (C 3 Cs)-cycloalkyl, O-(C 3 -Cs)-cycloalkyl, (C-Cs)-cycloalkenyl, 0-(C 3
-C
8
)
cycloalkenyl, (C 2
-C
6 )-alkynyl, (Co-Cs)-alkylene-aryl, O-(Co-C 8 )-alkylene aryl, S-aryl, N(R39)(R40), S0 2
-CH
3 , COOH, COO-(CI-C 6 )-alkyl, CON(R41)(R42), N(R43)CO(R44), N(R45)SO 2 (R46), CO(R47), 20 (CR48R49).-O(R50); R39,R40,R41,R42,R43,R45 independently of one another H, (CI-Cs)-alkyl; or 25 R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N (Ci-C 6 )-alkyl, oxygen and sulfur; 30 R44, R46, R47 independently of one another H, (CI-C 8 )-alkyl, aryl; 5 R48, R49 independently of one another H, (Ci-C 8 )-alkyl; R50 H, (Ci-C)-alkyl; 5 x 1,2,3,4; Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR5 I R52)y- in which one or more 10 (CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C; Y 0, S, N(R53), CO, SO, S02; 15 R51, R52 independently of one another H, (CI-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings; y 1,2,3,4,5,6; 20 R53 H, (Ci-Cs)-alkyl; E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , 25 oxo, 0-(CI-C 6 )-alkyl, 0-(Ci-C4)-alkoxy-(Ci-C 4 )-alkyl, S-(CI-C 6 )-alkyl, (Ci
C
6 )-alkyl, (C 2
-C
6 )-alkenyl, (C3-C 8 )-cycloalkyl, O-(C 3
-C
8 )-cycloalkyl, (C 2 C 6 )-alkynyl, (Co-Cs)-alkylene-aryl, O-(Co-Cs)-alkylene-aryl, S-aryl, N(R54)(R55), S0 2
-CH
3 , COOH, COO-(Ci-C 6 )-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SO 2 (R6 1), CO(R62) and be mono- or bicyclic; 30 R54,R55,R56,R57,R58,R60 independently of one another H, (CI-Cs)-alkyl; 6 R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N 5 (CI-C 6 )-alkyl, oxygen and sulfur; R59, R6I, R62 independently of one another H, (CI-C 8 )-alkyl, aryl; 10 K a bond, a group of the formula -(CR63R64),- in which one or more (CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C=C, C=C; Z 0, S, N(R65), CO, SO, SO 2 ; 15 R63, R64 independently of one another H, (CI-Cs)-alkyl, hydroxy, (C;-C 6 )-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings; 20 z 1, 2, 3, 4, 5, 6; preferably 2, 3, 4, 5, 6; R65 H, (CI-Cs)-alkyl; RI11 H, (Ci-Cg)-alkyl, (CI-C 4 )-alkoxy-(CI-C 4 )-alkyl, (C 3 -Cs)-alkenyl, (C 3
-C
8
)
25 alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br,
CF
3 , NO 2 , CN, (Ci-C 6 )-alkyl, O-(Ci-C 8 )-alkyl, (Ci-C 4 )-alkoxy-(CI-C 4
)
alkyl, (Co-C 8 )-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, 30 hydroxy-(CI-C 4 )-alkyl, COO(R69), N(R70)CO(C-C 6 )-alkyl, N(R71)(R72) or SO 2
CH
3
;
7 R66, R67, R68, R69, R70, R71, R72 independently of one another H, (Ci-C 8 )-alkyl; or R67 and R68, R71 and R72 5 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N (C-C)-alkyl, oxygen and sulfur; or 10 the N-oxides thereof and the physiologically tolerated salts thereof. The invention relates to compounds of the formula I in the form of their racemates, enantiomer-enriched mixtures and pure enantiomers and to their diastereomers and 15 mixtures thereof. The alkyl, alkenyl and alkynyl radicals in the substituents Ri, R2, R3, R4, R5, R6, R7, R8, R9, R10, R 1, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41., R42, 20 R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83 and R84 may be either straight-chain, branched or optionally halogenated. 25 In a further embodiment, the alkyl, alkenyl and alkynyl radicals in the substituents RI, R2, R3, R4, R5, R6, R7, R8, R9, RIO, RIl, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62. R63, R64, R65, R66, R67, R68, R69, R70, R71, 30 R72, R73, R74, R75, R76, R77, R78, R79. R80, R81, R82, R83 and R84 may be both straight-chain, branched and/or optionally substituted by substituents such as aryl, heteroaryl, alkoxy or halogen. This also applies if the alkyl, alkenyl and alkynyl radicals are part of another group, for example part of an alkoxy group (such as (CI-C 4 )-alkoxy- 8
(CI-C
4 )-alkyl)). Suitable halogens are fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, particularly preferably fluorine. Examples of alkyl groups are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl. 5 Included therein are both the n isomers of these radicals and branched isomers such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl etc. Unless described otherwise, the term alkyl additionally includes alkyl radicals which are unsubstituted or optionally substituted by one or more further radicals, for example 1, 2, 3 or 4 identical or different radicals such as aryl, heteroaryl, alkoxy or halogen. It is 10 moreover possible for the additional substituents to occur in any position of the alkyl radical. Cycloalkyl means for the purposes of the present application cycloalkyl and cycloalkyl alkyl(alkyl which is substituted in turn by cycloalkyl, e.g. cyclopropylmethyl), where 15 cycloalkyl has at least 3 carbon atoms. Examples of cycloalkyl radicals are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl. Optional possibilities are also polycyclic ring systems such as decalinyl, norbornanyl, bornanyl or adamantanyl. The cycloalkyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example for the alkyl 20 radicals. Examples of alkenyl and alkynyl groups are: vinyl, 1-propenyl, 2-propenyl (allyl), 2-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, ethynyl, 1-propynyl, 2-propynyl (propargyl), I -butynyl, 2-butynyl or 3-butynyl. 25 Cycloalkenyl means for the purposes of the present application cycloalkenyl radicals and cycloalkenyl-alkyl radicals (alkyl which is substituted by cycloalkenyl), which comprise at least three carbon atoms. Examples of cycloalkenyl are: cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. The alkenyl radicals and cycloalkenyl radicals may have 30 one to three conjugated or unconjugated double bonds (thus also alk-dienyl and alk-trienyl radicals), preferably one double bond in a straight or branched chain. The same applies to the triple bonds in alkynyl radicals. The alkenyl and alkynyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example 9 for the alkyl radicals. Aryl refers in the present invention to radicals derived from monocyclic or bicyclic aromatic compounds comprising no ring heteroatoms. Where aryl refers to systems which 5 are not monocyclic, the saturated form (perhydroform) or the partially unsaturated form (for example the dihydroform or tetrahydroform) is also possible, where the respective forms are known and stable, for the second ring. The term aryl also includes in the present invention for example bicyclic radicals in which both rings are aromatic and bicyclic radicals in which only one ring is aromatic. Examples of aryl are: phenyl, naphthyl, 10 indanyl, 1,2-dihydronaphthenyl, I,4-dihydronaphthenyl, indenyl or 1,2,3,4-tetrahydronaphthyl. Aryl is particularly preferably phenyl or naphthyl. The term "aryl" thus means in particular a phenyl or naphthyl group. Heteroaryl radicals mean radicals derived from monocyclic or bicyclic aromatic 15 compounds comprising ring heteroatoms, preferably N, 0 or S. Otherwise, the statements made about aryl radicals apply to heteroaryl radicals. The aryl and heteroaryl radicals may be unsubstituted or substituted by one or more further radicals. Suitable further radicals are listed by way of example above for the alkyl radicals. 20 The compounds of the formula I may comprise one or more centers of asymmetry. The compounds of the formula I may therefore be in the form of their racemates, enantiomer enriched mixtures, pure enantiomers, diastereomers and diastereomer mixtures. The present invention includes all these isomeric forms of the compounds of the formula I. 25 These isomeric forms can be obtained by known methods even if not expressly described in some cases. Mono-, bi- or spirocyclic rings may be saturated, partially saturated or unsaturated and also bridged. 30 C=C means a group of the formula R'C=CR" in which R' and R" are independently of one another H, (CI-C 8 )-alkyl, preferably H.
10 In the case where RI and R2 together with the nitrogen atom to which they are bonded form a ring, this ring may be substituted by one or more of the substituents mentioned. Pharmaceutically acceptable salts are particularly suitable for medical applications because 5 their solubility in water is higher than the initial or basic compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, 10 ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acids. The chloride salt is particularly preferably used for medical purposes. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium 15 and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine. Salts with a pharmaceutically unacceptable anion likewise fall within the scope of the invention as useful intermediates for preparing or purifying pharmaceutically acceptable 20 salts and/or for use in nontherapeutic, for example in vitro, applications. The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound according to the invention of the formula I, for example an ester, which is able on administration to a mammal such as, for example, a human to 25 form (directly or indirectly) a compound of the formula I or an active metabolite thereof. The physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound according 30 to the invention. These prodrugs may themselves be active or not. The compounds according to the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms I1 of the compounds according to the invention lie within the scope of the invention and are a further aspect of the invention. All references hereinafter to "compound(s) of formula (I)" refer to compound(s) of the 5 formula (I) as described above, and the salts, solvates and physiologically functional derivatives thereof as described herein. If radicals or substituents can occur more than once in the compounds of the formula I, they may all independently of one another have the stated meanings and be identical or 10 different. In a preferred embodiment, the meanings in the compounds of the formula I are RI, R2independently of one another H, (CI-Cs)-alkyl, -(CR13RI4)-R12, (C-C 4 )-alkoxy
(C-C
4 )-alkyl, (C 3
-C
8 )-alkenyl, (C 3
-C
8 )-alkynyl, CO-(C-Cs)-alkyl, -CO
(CH
2 )o -R 12, CO(C(R 15)(R 16))qN(R 17)(R 18), CO(C(R 19)(R20)),O(R21); 15 or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C 6 )-alkyl, 20 O-(C-Cg)-alkyl, (C 1
-C
4 )-alkoxy-(C-C 4 )-alkyl, hydroxy-(CI-C4)-alkyl, (Co Cs)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(CI-C 6 )-alkyl or N(R27)(R28); R 12 OH, 0-(C 1
-C
6 )-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 25 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, 0-(CI-C 6 )-alkyl, (C 1
-C
4 )-alkoxy-(C 1
-C
4 )-alkyl, S-(C-C 6 )-alkyl, (Ci
C
6 )-alkyl, (C 2
-C
6 )-alkenyl, (C 3 -C)-cycloalkyl, (C 2
-C
6 )-alkynyl, O-(Co-C 8
)
30 alkylene-aryl, (Co-Cs)-alkylene-aryl, N(R34)(R35), CO(C-C 6 )-alkyl and COO(R36); and 12 R6, R7, R8, R9 independently of one another H, (C-Cs)-alkyl; where the further radicals and groups in the compounds of the formula I have the meanings 5 mentioned hereinbefore and preferred meanings mentioned hereinafter. In a further preferred embodiment, the present invention relates to compounds of the formula I the meanings are: 10 RI, R2independently of one another H, (CI-Cs)-alkyl, -(CR13R14) 0 -R12, (CI-C 4 )-alkoxy (CI-C4)-alkyl, (C 3 -Cs)-alkenyl, CO-(Ci-Cs)-alkyl, -CO-(CH 2 )o -RI2, CO(C(R 15)(R 16))gN(R 17)(R 18), CO(C(R 19)(R20)),O(R21); or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10 15 membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (C-C)-alkyl, O-(Ci-C 4 )-alkyl,
(C
1 -C4)-alkoxy-(Cr-C 4 )-alkyl, hydroxy-(C-C 4 )-alkyl, (Co-C 2 )-alkylene-aryl, 20 oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C-C 6
)
alkyl, N(R27)(R28) or SO 2
CH
3 ; preferably independently of one another H, (CI-C)-alkyl, -(CR13R14)o-R12, (C 1
-C
4 )-alkoxy-(Cr-C4)-alkyl, CO-(C-Cs)-alkyl, -CO
(CH
2 )-R 12, CO(C(R 15)(R 16))qN(R I7)(R 18), CO(C(R19)(R20))sO(R21); 25 or R I and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (CI-C 6 )-alkyl, O-(Cl-C 4
)
30 alkyl, (C 1
-C
4 )-alkoxy-(C-C4)-alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R22), hydroxy, N(R27)(R28) or SO 2
CH
3 ; particularly preferably independently of one another H, (CI-Cs)-alkyl, (CRl3Rl4)o-R12, (C 1
-C
4 )-alkoxy-(Ci-C 4 )-alkyl, CO-(C-Cs)-alkyl, -CO- 13
(CH
2 )o-R 12, CO(C(R 15)(R 16))qN(R 17)(R 18), or R I and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, 5 where the heterocyclic ring system may additionally be substituted by F,
(CI-C
6 )-alkyl, (CI-C4)-alkoxy-(C-C 4 )-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28); o 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4; particularly preferably 0, 1, 2, 3; 10 q 1, 2, 3; preferably I or 2; s 0, 1, 2, 3, 4; preferably 0, 1, 2, 3; particularly preferably 0, 1, 2; 15 R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (Ci-C 6 )-alkyl; or R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to 20 which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N (Ci-C)-alkyl, oxygen and sulfur; the ring is preferably pyrrolidine, piperidine, N-methylpiperazine, morpholine; 25 R12 OH, 0-(CI-C 6 )-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF 3 , CN, oxo, 0-(Ci-C 6 )-alkyl,
(CI-C
4 )-alkoxy-(Ci-C 4 )-alkyl, (Ci-C 6 )-alkyl, O-(Co-Cs)-alkylene-aryl, (CO 30 Cs)-alkylene-aryl, N(R34)(R35), CO(CI-C 6 )-alkyl, COO(R36), S(O)(R37); preferably OH, O-(CI-C)-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, 0 and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, 14 OH, CF 3 , CN, oxo, 0-(CI-C 6 )-alkyl, (CI-C 4 )-alkoxy-(Ci-C 4 )-alkyl, (CI-C 6
)
alkyl, (Co-C 2 )-alkylene-aryl, N(R34)(R35), CO(CI-C 6 )-alkyl; particularly preferably OH, O-(Ci-C 6 )-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, 0 5 and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (Ci-C 6 )-alkyl, CO(CI-C 6 )-alkyl; u 0, 1, 2; preferably 0 or 2; particularly preferably 2; 1o R34, R35 independently of one another H, (Ci-C 8 )-alkyl; or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 15 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups; R36, R37 H, (C I-C 8 )-alkyl; 20 R13, R14 independently of one another H, (Ci-C 8 )-alkyl, hydroxy-(CI-C 4 )-alkyl, OH, (C I-C 4 )-alkoxy-(C 1
-C
4 )-alkyl; R29, R30, R3I 25 independently of one another H, (CI-Cs)-alkyl; R3 H, (CI-C 6 )-alkyl; preferably H; R4, R5 independently of one another H, (CI-C 6 )-alkyl, OH, O-(Ci-C 6 )-alkyl, 0 30 CO(CI-C 6 )-alkyl, S-(CI-C 6 )-alkyl; preferably independently of one another H, (CI-C 6 )-alkyl, OH, O-(CI-C 6 )-alkyl, O-CO(CI-C 6 )-alkyl; particularly preferably independently of one another H, OH, O-(Ci-C 6 )-alkyl, very particularly preferably H; 15 R6, R7, R8, R9 H; or 5 R6 and R7, R8 and R9 independently of one another optionally oxo; R6, R7, R8, R9 are preferably H; n 1 10 m I or 2; preferably 1; A, B, D, G independently of one another N, C(R38); or 15 the groups A and B or D and G are in each case C(R38) and together form an ortho-phenylene unit so that the overall result is a 1,4-bisubstituted naphthalene system; preferably A, B, G and D are independently of one another N, C(R38); particularly preferably D and G are C(R38) and either A or B is N, with the 20 respective other group B or A being C(R38); very particularly preferably B is N, C(R38); and A, D, G C(R38); especially preferably A, B, D, G are C(R38); 25 R38 H, F, Cl, Br, CF 3 , CN, O-(Ci-C 6 )-alkyl, O-(CI-C4)-alkoxy-(CI-C 4 )-alkyl, S
(CI-C
6 )-alkyl, (C I-C 6 )-alkyl, (Co-C 8 )-alkylene-aryl, O-(Co-C 8 )-alkylene-aryl, N(R39)(R40), S0 2
-CH
3 , CON(R41)(R42), N(R43)CO(R44), CO(R47), (CR48R49),-O(R50); preferably H, F, Cl, Br, CF 3 , CN, O-(Cf-C 6 )-alkyl, (CI-C 6 )-alkyl, S0 2
-CH
3 , 30 CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49).-O(R50); particularly preferably H, F, Cl, CF 3 , CN, (Ci-C 6 )-alkyl, -(CR48R49)x-O(R50); 16 R39,R40,R41,R42,R43 independently of one another H, (Ci-C 8 )-alkyl; or 5 R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N (CI-C)-alkyl, oxygen and sulfur; 10 R44, R47 independently of one another H, (CI-Cs)-alkyl, aryl; preferably independently of one another H, (Ci-Cs)-alkyl; R48, R49 H; 15 R50 H, (CI-C 6 )-alkyl; x 1, 2; preferably 1; 20 Het five-membered aromatic heterocycle, preferably A' Y'Y X'-Y, XI-A' A'-X' \\ I \\ / \ i X' X' N N Y=Z' orZ'Y 25 in which A' is 0, S, NR73, X', Y' and Z' 17 are independently of one another CR74 or N, and R73, R74 are independently of one another H, (Ci-C 8 )-alkyl; Het is particularly preferably selected from the group consisting of 5 oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles; X a bond, a group of the formula -(CR51 R52)y- in which one or more 10 (CR5lR52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, CEC; preferably a bond, CH 2
-CH
2 , CH 2 Y, YCH 2 , (R75)YCH 2 , CH 2 -NCO(R75), CH 2 CON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C=C; particularly preferably a bond, CH 2 CH 2 , C(R76)(R77), N(R75), CH 2 Y, CH 2 Y(R75), CH 2 -NCO(R75), 15 CH 2 CON(R75); C=C; very particularly preferably a bond, CH 2
-CH
2 , C(R76)(R77), C=C, (R75)YCH 2 , CH 2 -NCO(R75); Y 0, S, N(R53), CO; preferably 0, S, N(R53); 20 R53 H, (Ci-Cs)-alkyl; R75,R76,R77,R78,R79 independently of one another H, (CI-Cs)-alkyl; 25 E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , 0
(CI-C
6 )-alkyl, 0-(Ci-C4)-alkoxy-(Ci-C4)-alkyl, S-(CI-C 6 )-alkyl, (Ci-C 6
)
alkyl, (C 2
-C
6 )-alkenyl, O-(C 3
-C
8 )-cycloalkyl, (C 2
-C
6 )-alkynyl, (Co-C 8
)
30 alkylene-aryl, O-(Co-C 8 )-alkylene-aryl, S-aryl, N(R54)(R55), S0 2
-CH
3 , N(R58)CO(R59), N(R60)SO 2 (R61), CO(R62) and be mono- or bicyclic; preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally 18 have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , 0-(Ci-C 6 )-alkyl, S-(CI-C 6 )-alkyl, (CI-C 6 )-alkyl, (C 2
-C
6 )-alkenyl, 0-(Co-C 8
)
alkylene-aryl, S-aryl, N(R54)(R55), S0 2
-CH
3 , N(R58)CO(R59), CO(R62) and be mono- or bicyclic; 5 particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 ,
OCF
3 , 0-(CI-C 6 )-alkyl, (Ci-C 6 )-alkyl, (C 2
-C
6 )-alkenyl, N(R54)(R55), S02
CH
3 , CO(R62), and which is very particularly preferably monocyclic; 10 e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, I,2,3,6-tetrahydropyridine, 4,5-dihydroisoxazole, oxazole; 15 R54, R55, R58, R60 independently of one another H, (Ci-Cs)-alkyl; R59, R61, R62 independently of one another H, (Ci-C 8 )-alkyl, aryl; preferably 20 independently of one another H, (CI-Cs)-alkyl; K 0, a bond, CH 2 O, OCH 2 , S, SO, S02, N(R80), N(R81)CO, CON(R82), (C(R83)(R84)),, CO, C=C, CaC, SCH 2 , SO 2
CH
2 ; preferably 0, a bond, CH 2 0, OCH 2 , N(R80), N(R81)CO, CON(R82), 25 (C(R83)(R84)),, CO, C-C, SCH 2 ; particularly preferably 0, a bond, CH 2 0,
OCH
2 , CON(R82), (C(R83)(R84)),, CO, CEC; v 1, 2, 3, 4; preferably 1, 2, 3; particularly preferably 1,2; 30 R80,R81,R82,R83,R84 independently of one another H, (Ci-C 8 )-alkyl; 19 RI1 H, (CI-Cs)-alkyl, (Ci-C 4 )-alkoxy-(C-C 4 )-alkyl, (C 3 -Cs)-alkenyl, (C 3
-C
8
)
alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, 5 CF 3 , CN, (C 1
-C
6 )-alkyl, O-(C-Cs)-alkyl, (C 1
-C
4 )-alkoxy-(C-C4)-alkyl, hydroxy-(C-C 4 )-alkyl, (Co-C 8 )-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C-C 6 )-alkyl, N(R71)(R72) or SO 2
CH
3 ; preferably (CI-Cs)-alkyl, (C-C4)-alkoxy-(C-C4)-alkyl, a 3 to 10-membered 10 mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, (Ci-C 6 )-alkyl, O-(Ci-Cs)-alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C -C 6 )-alkyl, N(R71)(R72) or SO 2
CH
3 ; 15 particularly preferably (C-Cs)-alkyl, (C 1
-C
4 )-alkoxy-(C 1
-C
4 )-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, (C-C 6 )-alkyl, O-(CI-Cs)-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(CI-C 6 )-alkyl, 20 or SO 2
CH
3 ; R66, R67, R68, R69, R70, R7 1, R72 independently of one another H, (C-Cs)-alkyl; or R67 and R68, R71 and R72 25 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N
(C-C
6 )-alkyl, oxygen and sulfur; or 30 the N-oxides thereof and the physiologically tolerated salts thereof. In a preferred embodiment of the invention, the radicals R I, R2, R 11, R38 and groups X, E, K have the following meanings: 20 RI, R2 independently of one another H, (Ci-Cs)-alkyl, -(CR13R14)o-R12, (CI-C 4
)
alkoxy-(Ci-C 4 )-alkyl, or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (CI-C 6
)
alkyl, O-(CI-C 4 )-alkyl, (CI-C4)-alkoxy-(C-C 4 )-alkyl, hydroxy-(CI-C 4
)
alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, 10 N(R27)(R28) or SO 2
CH
3 ; preferably independently of one another H, (Ci-C 8 )-alkyl, -(CRl3Rl4)"-, R12, (Ci-C 4 )-alkoxy-(C,-C4)-alkyl, or Rl and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 15 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (Ci-C 6 )-alkyl, O-(Ci-C4)-alkyl, (CI-C4)-alkoxy-(C-C 4 )-alkyl, hydroxy
(CI-C
4 )-alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28); 20 very particularly preferably independently of one another H, (Ci-Cs)-alkyl, or RI and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to I additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may 25 additionally be substituted by (CI-C 6 )-alkyl; especially preferably independently of one another H, (Ci-C 8 )-alkyl; o 0, 1,2,3,4; 30 R22, R23, R24, R27, R28 independently of one another H, (CI-C 6 )-alkyl; or R23 and R24, R27 and R28 21 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N (Ci-C 6 )-alkyl, oxygen and sulfur; 5 R 12 OH, O-(Ci-C 6 )-alkyl, CN, 3-12 membered mono-, bi- or spirocyclic ring which may comprise I to 3 heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further substituents such as F, OH,
CF
3 , CN, oxo, (CI-C 6 )-alkyl, (Co-C 2 )-alkylene-aryl, N(R34)(R35), 10 COO(R36), CO(CI-C 6 )-alkyl; R34, R35 independently of one another H, (Ci-C 4 )-alkyl; 15 R36 H, (CI-C 6 )-alkyl; R13, R14 independently of one another H, (CI-C 8 )-alkyl, hydroxy-(CI-C 4 )-alkyl, OH, (CI -C 4 )-alkoxy-(C I-C 4 )-alkyl; 20 R38 H, F, Cl, Br, CF 3 , CN, (Ci-C 6 )-alkyl; X a bond, CH 2
CH
2 , C(R76)(R77), N(R75), C=C, (R75)YCH 2 ,
CH
2 -NCO(R75), CH 2 CON(R75); 25 Y 0, S, N(R53), CO R75, R76, R77 independently of one another H, (CI-Cs)-alkyl; 30 R53 H, (Ci-Cs)-alkyl; E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally have 22 substituents from the group of H, F, Cl, Br, CF 3 , OH, CN, OCF 3 , O-(CI-C 6
)
alkyl, (CI-C 6 )-alkyl, S0 2
-CH
3 , CO(R65); R65 H, (CI-Cs)-alkyl; 5 K 0, a bond, CH 2 0, CH 2 , OCH 2 , S, SO 2 , N(R80), N(R8I)CO, CON(R82), (C(R83)(R84)),, CO, C=C, SCH 2 , SO 2
CH
2 ; preferably 0, a bond, CH 2 0, CH 2 , OCH 2 , N(R80), CsC; 10 v 1,2,3; R80,R81,R82,R83,R84 independently of one another H, (CI-Cs)-alkyl; 15 RiI (CI-Cs)-alkyl, (Ci-C 4 )-alkoxy-(C 1
-C
4 )-alkyl, a 3 to 10-membered mono-, bi or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, (Ci-C 6 )-alkyl, O-(Ci-C 8
)
alkyl, oxo, CO(R66), hydroxy, N(R70)CO(CI-C 6 )-alkyl, or SO 2
CH
3 ; 20 R66, R70 independently of one another H, (Ci-Cs)-alkyl; the N-oxides thereof and the physiologically tolerated salts thereof. 25 Particularly preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1, and in the case where 30 the total number of nitrogen atoms is 1, particularly preferably A or B are N, and very particularly preferably B is N.
23 Very particularly preferred compounds of the formula I are those in which n is l and m is l or 2. 5 Especially preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1, and in the case where 10 the total number of nitrogen atoms is 1, particularly preferably A or B are N, and very particularly preferably B is N. n is l and 15 m is I or 2. The radical R38 has the aforementioned meanings. Especially preferred compounds of the formula I are those in which 20 Het is selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles. 25 The further radicals may have the aforementioned meanings in the aforementioned preferred embodiments. In a very particularly preferred embodiment, the present application relates to compounds of the formula IA 30 24 "E, ~ / N R1 R11 K E X-H et NNR 2 A in which the meanings are 5 Het X'Yr A-X in which A' is O, S, X' and Y' 10 are independently of one another CR74 or N, and R74 are independently of one another H, (CI-C 8 )-alkyl; A, B are CH or CF, where in the case of CF only one of the two groups A or B is CF and the other group is CH; 15 R I, R2 independently of one another H, (Ci-Cs)-alkyl, -(CRI3RI4) 0 -R12, (CI-C 4
)
alkoxy-(CI-C 4 )-alkyl, (C 3 -Cs)-alkenyl, (C 3 -Cs)-alkynyl, CO-(Ci-Cs)-alkyl,
-CO-(CH
2 )o-R 12, CO(C(R I 5)(R 16))qN(R 17)(R 18), CO(C(R19)(R20)),O(R21); or RI and R2 form together with the nitrogen 20 atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C)-alkyl, 0-(Ci-Cs)-alkyl, (CI-C4)-alkoxy 25 (Ci-C 4 )-alkyl, hydroxy-(CI-C 4 )-alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(CI-C 6 )-alkyl, N(R27)(R28) or SO 2
CH
3
;
25 particularly preferably independently of one another H, (CI-Cs)-alkyl, -(CR1 3R 14),-R 12, (CI-C 4 )-alkoxy-(Ci-C 4 )-alkyl, CO-(C 1 -Cg)-alkyl,
-CO-(CH
2 )o-R12; or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (CI-C)-alkyl, O-(C-Cs)-alkyl, (Ci-C 4 )-alkoxy-(C-C 4 )-alkyl, hydroxy-(C
C
4 )-alkyl, (Co-C 8 )-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxyl, 10 N(R26)CO(CI-C 6 )-alkyl, N(R27)(R28); very particularly preferably independently of one another H, (CI-Cs)-alkyl, (CR13R14) 0 -R12, (C-C 4 )-alkoxy-(C-C4)-alkyl, -CO-(CH 2 )o-R12; or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 7-membered monocyclic ring which, apart from the nitrogen atom, may 15 include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (CI-C 6 )-alkyl, O-(C 1 -Cs)-alkyl, hydroxy-(C-C 4
)
alkyl, CO(R22), CON(R23)(R24), hydroxy, N(R26)CO(C-C 6 )-alkyl, N(R27)(R28); 20 especially preferably independently of one another H, (CI-C 8 )-alkyl, or RI and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to I additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be 25 substituted by (CI-C 6 )-alkyl; further very particularly preferably independently of one another H, (C-Cs)-alkyl; o 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4; 30 q, s independently of one another 0, 1, 2, 3, 4; R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 26 independently of one another H, (CI-C)-alkyl; R17 and Rl8, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to 5 which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur; R 12 OH, O-(C1-C)-alkyl, CN, COO(R29), CON(R30)(R3 1), N(R32)(R33), 3-12 10 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, 0-(CI-C 6 )-alkyl, (CI-C 4 )-alkoxy-(Cj-C 4 )-alkyl, S-(Ci-C 6 )-alkyl, (Ci
C
6 )-alkyl, (C 2
-C
6 )-alkenyl, (C 3 -Cs)-cycloalkyl, (C 2
-C
6 )-alkynyl, O-(Co-C 8
)
15 alkylene-aryl, (Co-Cs)-alkylene-aryl, N(R34)(R35), CO(CI-C)-alkyl, COO(R36) and S(O)(R37); particularly preferably OH, O-(Ci-C)-alkyl, CN, CON(R30)(R31), N(R32)(R33), 3-7 membered monocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-7 membered ring 20 may comprise further substituents such as F, Cl, OH, CF 3 , CN, OCF 3 , oxo,
O-(CI-C
6 )-alkyl, (CI-C4)-alkoxy-(CI-C4)-alkyl, S-(CI-C 6 )-alkyl, (CI-C 6
)
alkyl, (C 2 -C)-alkenyl, (C 3 -Cs)-cycloalkyl, (C 2
-C
6 )-alkynyl, O-(CO-C 8
)
alkylene-aryl, (CO-Cs)-alkylene-aryl, N(R34)(R35) and CO(CI-C 6 )-alkyl; 25 u 0, 1,2; R34, R35 independently of one another H, (CI-Cs)-alkyl; 30 R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 27 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups; R36, R37 H, (Ci-Cs)-alkyl; 5 R13, R14 independently of one another H, (CI-C 8 )-alkyl, hydroxy-(Ci-C4)-alkyl, OH, (Ci-C 4 )-alkoxy-(Ci-C4)-alkyl; R29, R30, R31 10 independently of one another H, (CI-Cs)-alkyl, (C 2
-C
6 )-alkenyl, (Co-C 8
)
alkylene-aryl; R32, R33 independently of one another H, (CI-C 6 )-alkyl or 15 R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring, which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups; 20 X a bond, a group of the formula -(CR51 R52)y- in which one or more -(CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, CaC; preferably a bond, CH 2
-CH
2 , CH 2 Y, YCH 2 , (R75)YCH 2 , CH 2 -NCO(R75), CH 2 CON(R75); C(R76)(R77), 25 C(R78)(R79)O, N(R75), C=C, CEC; particularly preferably a bond, CH 2 CH 2 , C(R76)(R77), N(R75), CH 2 Y, CH 2 Y(R75), CH 2 -NCO(R75),
CH
2 CON(R75); C=C; very particularly preferably a bond, CH 2
-CH
2 , C(R76)(R77), C=C; (R75)YCH 2 , CH 2 -NCO(R75); 30 Y 0, S, N(R53), CO, SO, SO 2 ; particularly preferably 0, S, N(R53), CO; very particularly preferably 0, N (R53); 28 R51, R52 independently of one another H, (CI-C 4 )-alkyl, where R51 and R52 in the y groups in each case can have the same or different meanings; y 1,2,3,4,5,6; 5 R53 H, (Ci-C 8 )-alkyl; E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, 0 and S, which may optionally have 10 substituents from the group of H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O-(Ci-C 6 )-alkyl, 0-(CI-C 4 )-alkoxy-(CI-C 4 )-alkyl, S-(CI-C 6 )-alkyl,
(CI-C
6 )-alkyl, (C 2
-C
6 )-alkenyl, (C 3 -Cs)-cycloalkyl, O-(C 3 -Cs)-cycloalkyl,
(C
2
-C
6 )-alkynyl, (Co-Cs)-alkylene-aryl, 0-(Co-Cs)-alkylene-aryl, S-aryl, N(R54)(R55), SO 2
-CH
3 , COOH, COO-(CI-C 6 )-alkyl, CON(R56)(R57), 15 N(R58)CO(R59), N(R60)SO 2 (R61), CO(R62) and be mono- or bicyclic; preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, OH, CN, CF 3 , OCF 3 , O-(C 1 C 6 )-alkyl, (CI-C 6 )-alkyl, (Co-Cs)-alkylene-aryl, O-(C 3 -Cs)-cycloalkyl, 20 N(R54)(R55), SO 2
-CH
3 , CON(R56)(R57), N(R58)CO(R59), N(R60)SO 2 (R61), CO(R62) and be mono- or bicyclic; particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, CF 3 , OCF 3 , O-(CI-C 6 )-alkyl, 25 (CI-C 6 )-alkyl, (Co-C 2 )-alkylene-aryl, 0-(C 3
-C
6 )-cycloalkyl, N(R54)(R55), CON(R56)(R57), N(R58)CO(R59), CO(R62) and be mono- or bicyclic; R54, R55, R56, R57, R58, R60 independently of one another H, (CI-Cg)-alkyl; 30 R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen 29 atom, may also include 0-1 further heteroatoms from the group of NH,
N-(CI-C
6 )-alkyl, oxygen and sulfur; R59, R6 I, R62 5 independently of one another H, (CI-Cg)-alkyl, aryl; K a bond, a group of the formula -(CR63R64)z-, in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, CaC, C=C; 10 preferably 0, a bond, CH 2 0, CH 2 , OCH 2 , S, S02, N(R80), N(R81)CO, CON(R82), (C(R83)(R84)),, CO, CEC, SCH 2 , SO 2
CH
2 ; Z 0, S, N(R65), CO, SO, SO 2 ; 15 R63, R64 independently of one another H, (CI-Cs)-alkyl, hydroxy, (CI-C 6 )-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings; z 1, 2, 3, 4, 5, 6, preferably 2, 3, 4, 5, 6; 20 R65 H, (Ci-Cs)-alkyl; RlI H, (Ci-Cs)-alkyl, (Ci-C 4 )-alkoxy-(Ci-C 4 )-alkyl, (C 3
-C
8 )-alkenyl, (C 3
-C
8
)
alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may 25 include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br,
CF
3 , NO 2 , CN, (CI-C 6 )-alkyl, 0-(CI-C 8 )-alkyl, (CI-C 4 )-alkoxy-(CI-C 4
)
alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(CI-C 4 )-alkyl, COO(R69), N(R70)CO(CI-C 6 )-alkyl, N(R71)(R72) 30 or SO 2
CH
3 ; preferably H, (Ci-Cs)-alkyl, (CI-C 4 )-alkoxy-(C 1
-C
4 )-alkyl, a 5 to 6 membered monocyclic ring which may include 0 to 3 heteroatoms selected 30 from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (Ci-C 6 )-alkyl, 0
(CI-C
8 )-alkyl, (CI-C4)-alkoxy-(CI-C 4 )-alkyl, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(CI-C 6 )-alkyl, N(R71)(R72) or SO 2
CH
3 ; 5 particularly preferably H, (CI-Cs)-alkyl, (CI-C4)-alkoxy-(CI-C 4 )-alkyl, a 5 to 6-membered monocyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C 6
)
alkyl or O-(CI-Cg)-alkyl; 10 R66,R67,R68,R69,R70,R71,R72 independently of one another H, (CI-Cs)-alkyl; or R67 and R68, R71 and R72 15 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur; or 20 the N-oxides thereof and the physiologically tolerated salts thereof. The compounds of the invention of the formula I and their precursors can be prepared by processes known to the skilled worker. 25 The preparation of compounds of the invention of the formula I is described below for the example of the preparation of [I ,3,4]-oxadiazoles ([a), [I ,3,4]-thiadiazoles (Ib) and [1,2,4] oxadiazoles (Ic): 31 N H N O 0 OR 0 N, H 0 R O R ORONH 2
NRR
2
H
2 N-NH2 xH 2 0 (N N
NRIR
2 NRR 2 (111) (IV) in which R is H, (CI-C 8 )-alkyl, and 5 RI and R2 have the aforementioned meanings; O R11K "E"X OH N v> C, PF KE X 0
NRR
2 + R1 N-N N- l N-- (la) 10 or Burgess' reagent 32 0 0 0 N )KN "kxE ,Rl 1 O O N X EKR1 R11, ,Es< H K X OH (IV) (V) TOTU N NR Lawesson's reagent N NRR 2 R11 N-N (Ib) in which R 1, R2, R 1 and X, E and K have the aforementioned meanings.
33 CN N N OI.N N, N / N NRR/2
NR
1 R( (X)(Xil) (XIII) 0 1) R11, KE, PyBOP 2) EDC, A O-N K X N (Ic)
NR
1
R
2 in which RI, R2, Rl I and X, E and K have the aforementioned meanings. 5 Use This invention further relates to the use of compounds of the formula I and their pharmaceutical compositions as MCH receptor ligands. The MCH receptor ligands of the invention are particularly suitable as modulators of the activity of the MCH1R. 10 The role of MCH in regulating the energy balance has now been well documented (Qu, D. et al.; Nature 1996, 380, 243-7; Shimada, M. et al. Nature 1998, 396, 670-4; Chen, Y. et al. Endocrinology 2002, 143, 2469-77; Endocrinology 2003, 144, 4831-40; Review: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511). 15 There are also indications that MCH antagonists can have a beneficial influence on centrally related disorders such as, for example, depression (Borowsky, B. et al.; Nature 34 Medicine 2002, 8, 825-30; Review: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495 511). Compounds of this type are particularly suitable for the treatment and/or prevention of 5 1. Obesity 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith. 10 Particular aspects in this connection are - hyperglycemia, - improvement in insulin resistance, - improvement in glucose tolerance, - protection of the pancreatic B cells 15 - prevention of macro- and microvascular disorders 3. Dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following factors: 20 - high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, - low HDL cholesterol concentration 4. Various other conditions which may be associated with the metabolic syndrome, such 25 as: - thromboses, hypercoagulable and prothrombotic stages (arterial and venous) - high blood pressure - heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy 30 5. Psychiatric indications such as - depression - anxiety states 35 - disturbances of the circadian rhythm - affection disorders - schizophrenia - addictive disorders 5 Formulations The amount of a compound of formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound 10 chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.001 mg to 100 mg, preferably from 0.3 mg to 100 mg (typically from 0.01 mg to 50 mg, preferably from 3 mg to 50 mg) per day per kilogram of body weight, for example 0.1-10 mg/kg/day, preferably 3-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 15 mg/kg, preferably from 0.3 mg to 1.0 mg/kg, which can most suitably be administered as infusion of from 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from I mg to 10 g of the active ingredient. Single doses may contain, for example, from I mg to 10 g of the active 20 ingredient. It is thus possible for ampoules for injections to contain, for example, from I mg to 100 mg, and for single-dose formulations which can be administered orally, such as, for example, tablets or capsules, to contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg, or in a further embodiment from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the aforementioned 25 weight data are based on the weight of the salt of the underlying free compound. For the prophylaxis or therapy of the abovementioned conditions, the compounds of formula (I) can be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not 30 hazardous for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet which may contain from 0.05% to 95% by weight of the active ingredient. Further pharmaceutically active substances may likewise be present, including other compounds of 36 formula (I). The pharmaceutical compositions according to the invention can be produced by one of the known pharmaceutical methods which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients. 5 Pharmaceutical compositions according to the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) used in each case. 10 Coated formulations and coated slow-release formulations also lie within the scope of the invention. Formulations resistant to acid and gastric fluid are preferred. Suitable coatings resistant to gastric fluid comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate. 15 Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water 20 in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. In general, the compositions are produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the 25 product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, where appropriate mixed with a binder, lubricant, inert diluent and/or a (plurality of) surface-active/dispersing 30 agent(s) in a suitable machine. Molded tablets can be produced by molding the compound which is in powder form and is moistened with an inert liquid diluent in a suitable machine.
37 Pharmaceutical compositions suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula (I) with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic. 5 Suitable pharmaceutical compositions for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular 10 or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound. 15 Suitable pharmaceutical compositions for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture. 20 Suitable pharmaceutical compositions for topical application to the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%. 25 Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an 30 adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%. As a special possibility, the active ingredient can be released as described, for example, in Pharmaceutical Research, 2(6): 318 (1986) by electrotransport or iontophoresis.
38 The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents. 5 The compounds are distinguished by their low toxicity and their few side effects. The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover 10 of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the 15 prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure. Combinations with other medicaments 20 In a further aspect of the invention, the compounds of the formula I can be administered in combination with one or more other pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are I. medicaments which lower blood glucose, antidiabetics, 25 2. active ingredients for the treatment of dyslipidemias, 3. antiatherosclerotic medicaments, 4. antiobesity agents, 5. antiinflammatory active ingredients 6. active ingredients for the treatment of malignant tumors 30 7. antithrombotic active ingredients 8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and 39 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes. They can be combined with the compounds of the invention of the formula I in particular 5 for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. 10 Further pharmacologically active substances suitable in particular are: Antidiabetics All antidiabetics mentioned in the Rote Liste 2001, chapter 12. They may be combined 15 with the compounds of the formula I of the invention in particular for a synergistic improvement of the effect. Administration of the active ingredient combination may take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients listed below are disclosed in the 20 USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001. Suitable antidiabetics include all insulins and insulin derivatives such as, for example, Lantus* or HMR 1964 or Apidra*, and other fast-acting insulins (see, e.g., US 6,221,633), 25 amylin, GLP-l and GLP-2 derivatives such as described in WO 01/04146 or else such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally effective hypoglycemic active ingredients. The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, 30 biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-l agonists, DPP-IV inhibitors, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, insulin sensitizers, activators of insulin receptor kinase, inhibitors of 40 GSK3-beta, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, for example inhibitors of glycogen phosphorylase, modulators of glucose uptake and glucose excretion, compounds which alter lipid metabolism and lead to a change in the lipid composition of the blood, such as antihyperlipidenic active 5 ingredients and antilipidemic active ingredients, e.g. HMGCoA reductase inhibitors, inhibitors of cholesterol transport/of cholesterol uptake, inhibitors of bile acid reabsorption or inhibitors of microsomal triglyceride transfer protein (MTP), compounds which reduce food intake and/or food absorption, PPAR and RXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells. 10 In one embodiment of the invention, the present compounds are administered in combination with insulin. In one embodiment of the invention, the compounds of the formula I are administered in 15 combination with substances which influence hepatic glucose production such as, for example, glycogen phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO 03/084923, WO 03/084922, WO 03/104188). In one embodiment, the compounds of the formula I are administered in combination with 20 a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride. In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide. 25 In one embodiment, the compounds of the formula I are administered in combination with a biguanide such as, for example, metformin. In a further embodiment, the compounds of the formula I are administered in combination 30 with a meglitinide such as, for example, repaglinide. In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research 35 Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]- 41 phenyl I methyl]-2,4-thiazolidinedione. In one embodiment, the compounds of the formula I are administered in combination with a DPPIV inhibitor as described, for example, in W098/19998, W099/61431, 5 W099/67278, W099/67279, WO01/72290, WO 02/38541, W003/040174, in particular P 93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloride), P-31/98, LAF237 (1 [2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile), TSO21 ((2S, 4S) 4-fluoro- I -[[(2-hydroxy- 1,1 -dimethylethyl)amino]acetyl]pyrrolidine-2-carbonitrile monobenzenesulfonate). 10 In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone. In one embodiment, the compounds of the formula I are administered in combination with 15 compounds with an inhibitory effect on SGLT-1 and/or 2, as disclosed directly or indirectly for example in PCT/EP03/06841, PCT/EP03/13454 and PCT/EP03/13455. In one embodiment, the compounds of the formula I are administered in combination with an a-glucosidase inhibitor such as, for example, miglitol or acarbose. 20 In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc. 25 Lipid modulators In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, 30 pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin. In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor (see, for example, US 6,245,744, US 6,221,897, US 6,277,83 1, EP 0 683 773, EP 0 683 774). 35 42 In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam. 5 In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor as described for example in WO 0250027, or ezetimibe, tiqueside, pamaqueside. In one embodiment of the invention, the compounds of the formula I are administered in 10 combination with an LDL receptor inducer (see, for example, US 6,342,512). In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax* (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, 15 ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6); Caromax is a carob containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hoechst, 65926 Frankfurt/Main). Combination with Caromax* is possible in one preparation or by separate administration of compounds of the formula I and Caromax*. Caromax* can in this connection also be administered in the form of food 20 products such as, for example, in bakery products or muesli bars. In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARalpha agonist. 25 In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate. In one embodiment of the invention, the compounds of the formula I are administered in 30 combination with nicotinic acid or niacin. In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, e.g. CP- 529, 414 (torcetrapib). 35 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor.
43 In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide. In one embodiment of the invention, the compounds of the formula I are administered in 5 combination with an antioxidant. In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor. 10 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor. In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor. 15 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist. Antiobesity agents 20 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor such as, for example, orlistat. In one embodiment, the further active ingredient is fenfluramine or dexfenfluramine. 25 In another embodiment, the further active ingredient is sibutramine. In another embodiment, the further active ingredient is rimonabant. In a further embodiment, the compounds of the formula I are administered in combination 30 with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl] cyclohexylmethyl amide; hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-I ,2,3,4-tetrahydronaphthalene-2-carboxylic 35 acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-cIpyridin-5-yl)- 1 (4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)), orexin antagonists (e.g. 1-(2- 44 methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea; hydrochloride (SB-334867-A)), CB1 antagonists/inverse agonists, H3 antagonists/inverse agonists (e.g. 3-cyclohexyl-1 (4,4-dimethyl- 1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan- 1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6 5 trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin agonists, P3 agonists (e.g. I-(4-chloro-3 methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl- IH-indol-6-yloxy)ethylamino]ethanol; hydrochloride (WO 01/8345 1)), MSH (melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g. {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2 10 ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525)); serotonin reuptake inhibitors (e.g. dexfenfluramines), mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7 yl)piperazine oxalic acid salt (WO 01/09111), BR53 agonists, galanin antagonists, ghrelin antagonists, MCH antagonists, mGluR5 antagonists, opioid antagonists, growth hormone 15 (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2 diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert butyl ester (WO 01/85695)), CNTF, CNTF derivatives (e.g. Axokine), TRH agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, 20 Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists (e.g. bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR-$ agonists. 25 In one embodiment of the invention, the further active ingredient is leptin. In one embodiment, the further active ingredient is dexamphetamine, amphetamine, mazindole or phentermine. 30 In one embodiment, the compounds of the formula I are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g. ramipril), medicaments which act on the angiotensin-renin system, calcium antagonists, beta blockers etc. 35 In one embodiment, the compounds of the formula I are administered in combination with medicaments having an antiinflammatory effect.
45 In one embodiment, the compounds of the formula I are administered in combination with medicaments which are employed for cancer therapy and cancer prevention. It will be appreciated that every suitable combination of the compounds of the invention 5 with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is to be regarded as covered by the scope of protection of the present invention. In two articles which appeared simultaneously in Nature (Nature 400, 261-264, 1999; Nature 400, 265-269, 1999), a highly specific receptor for melanine concentrating hormone 10 (MCH) was described separately by two research groups. MCH assumes important functions in controlling food intake. Compounds acting on the MCH receptor therefore have an anorectic effect and are suitable for the treatment of obesity. Testing for an anorectic effect of the compounds of the invention of the formula I was therefore carried out as follows. 15 Functional measurements to find IC50 values The cloning of the cDNA for the human MCH receptor, preparation of a recombinant HEK293 cell line which expresses the human MCH receptor, and functional measurements 20 with the recombinant cell line took place in analogy to the description by Audinot et al. (J. Biol. Chem. 276, 13 554-13 562, 2001). A difference from the reference was, however, the use of the plasmid pEAK8 from EDGE Biosystems (USA) to construct the expression vector. The host used for the transfection was a transformed HEK cell line named "PEAK Stable Cells" (likewise from EDGE Biosystems). The functional measurements of the 25 cellular calcium flux after addition of agonist (MCH) in the presence of ligand of the invention took place with the aid of the FLIPR apparatus from Molecular Devices (USA) using the protocols of the apparatus manufacturer. Biological activity testing The IC50 values measured for exemplary compounds 33, 96 and 97 under the 30 aforementioned conditions were of the order of from 0.01 to 10 pM.
46 General explanations a) Mode of drawing the structural formulae Only non-H atoms are depicted for clarity in the structural formulae of the given examples. 5 Carbon atoms are not written out as "C". b) Salt forms Many of the compounds of the invention are bases and can form salts with appropriately strong acids. In particular, after purification of the compounds by HPLC chromatography 10 using a trifluoroacetic acid-containing mobile phase they may be in the form of hydrotrifluoroacetates. These can be converted into the free bases shown by simple treatment of a solution of the salts for example with sodium carbonate solution. c) Units of the characterizing data 15 The unit of the stated molecular weights is "g/mol". Peaks observed in the mass spectrum are indicated as integral quotient of the molar molecular ion mass and the charge of the molecular ion (m/z). Abbreviations 20 Unless indicated otherwise, the abbreviations in the examples below have the following meaning: NaBH 3 CN = sodium cyanoborohydride DMF = N,N-dimethylformamide 25 EDC = I-(3-dimethylaminopropyl)-3-ethylcarbodiimide THF = tetrahydrofuran DMSO = dimethyl sulfoxide HOBt = I -hydroxybenzotriazole HOAt = 1-hydroxy-7-azabenzotriazole 30 HCI = hydrochloric acid HPLC = high performance liquid chromatography PyBOP = benzotriazol- I -yloxytris(pyrrolidino)phosphonium hexafluorophosphate 47 TOTU = O[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate eq = equivalents 5 Example I (1-{4-[5-(4-Butoxyphenyl)-[1,3,4]oxadiazol-2-yl]phenyl pyrrolidin-3-yl)dimethylamine O N- 0 N N-N Method A 10 A mixture of 4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), 4-butoxy benzoic acid (78 mg), 2-chloro- 1,3-dimethyl-2-imidazolium hexafluorophosphate (112 mg), N,N-diisopropylethylamine (0.14 ml) and dichloromethane (5 ml) was stirred for 12 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was obtained in this way; 15 MS (ESI): 407 (M+H+). 4-(3-Dimethylaminopyrrolidin- 1-yl)benzohydrazide A mixture of ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate (2.0 g), hydrazine hydrate (3.8 g) and ethanol (7 ml) was boiled under reflux for 15 hours. After cooling to 5'C, the 20 resulting precipitate was filtered off with suction. The product with the molecular weight of 248.33 (C I 3H20N40) was obtained in this way; MS (ESI): 249 (M+H+). Ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate A mixture of ethyl 4-fluorobenzoate (4.47 g), dimethylpyrrolidin-3-ylamine (3.04 g), 25 potassium carbonate (3.68 g) and dimethyl sulfoxide (20 ml) was heated at 130 0 C for 7 hours. After cooling, the mixture was diluted with water and extracted with methyl tert butyl ether. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated. The product with the molecular weight of 262.35 (C15H22N202) was obtained in this way; MS (ESI): 263 (M+H+).
48 Example 2 Dimethyl-(I - {4-[5-(2-phenoxyethylsulfanylmethyl)-[ 1,3,4]oxadiazol-2-yl]phenyl} pyrrolidin-3-yl)amine N. ' N S 0 1 a N5 N-N 5 4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was reacted with (2-phenoxy ethylsulfanyl)acetic acid by Method A. The product with the molecular weight of 424.57 (C23H28N402S) was obtained in this way; MS (ESI): 425 (M+H+). 10 Example 3 Dimethyl-(l -{4-[5-(4-phenoxyphenyl)[ l,3,4]oxadiazol-2-yl]phenyl pyrrolidin-3-yl)amine O N N-NN 15 Method B A mixture of N'-[4-(3-dimethylaminopyrrolidin-1-yl)benzoyl]-4-phenoxybenzohydrazide (178 mg), methoxycarbonylsulfamoyltriethylammonium hydroxide (Burgess' reagent) (96 20 mg) and 5 ml of toluene was stirred at 60'C for 1 h. After the reaction was complete, the reaction mixture was filtered, and the filtrate was washed twice with ethyl acetate. The combined organic phases were subsequently washed with 5% strength sodium carbonate solution and then dried over Chromabond XTR. Volatiles were removed and the residue 49 was purified by preparative HPLC. The product with the molecular weight of 426.21 (C26H26N402) was obtained in this way; MS (ESI): 427.21 (M+H+). N'-[4-(3-Dimethylaminopyrrolidin-I -yl)benzoyl]-4-phenoxybenzohydrazide 5 A mixture of 4-(3-dimethylaminopyrrolidin-I-yl)benzohydrazide (100 mg), 4-phenoxybenzoic acid (77.5 mg), 1-propanephosphonic anhydride 50% in dichloromethane (256 mg), N,N-diisopropylethylamine (0.208 ml) and DMF (3 ml) was stirred at room temperature for 72 h. The reaction mixture was then filtered, washed twice with ethyl acetate and shaken with 0.5N NaOH. Volatiles were removed and the residue 10 was purified by preparative HPLC. The product with the molecular weight of 444.54 was obtained in this way; MS (ESI): 445.24 (M+H+). 4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was prepared as described in method A, with I eq of Burgess' reagent being added once again in some cases after heating for I h 15 in the cyclization step, and then heating at 60'C being continued for 1 hour. Compounds 4-93 in table I were synthesized by method B.
50 Ex Structure Molecular formula MW MW calc measured 4 C27H28N402 440.22 441.24 N-N 5 C26H34N402 434 27 435.28 6 N- C27H28N402 440.22 441.27 N- N 8 C27H34N402 446.27 447.27 N N 9 C27H32N402 444.25 445.26 N-N.
N-N-
-NN 1 _ C23H26N403 406.20 407.22 ~ , ~ JN /1
ON-N
51 12 N- C22H23N502 389.19 390.16 O N 13 C27H28N402 440.22 441.23 N-N 14 N C28H30N403 470.23 471.21 N-N 15 _C28H30N402 454.24 455.25 16N- C26H26N402 426.21 427.29 17 N_ C27H28N402 440.22 441.23 0) N 18 _C27H28N40 425.23 425.24 N-N 19 \N- C27H26N402 438.21 439.28 20 z;N- N 20 N C24H23CIN4O2 434.15 436.02
N
cl- N- 52 21 \N_ C26H32N40 416.26 417.36 N--N 22 \N- C2.4-H30N403- 422.23 424.02 .- ~0 N-N 23 sN C27H28N402 440.22 441.27 N_/ N-N 24 N_ C22H26N403 394.20 395.21 N-N 25 _ C28H30N403 470.23 471.25 26 C29H29N502 479.23 480.39 27 _ C22H23F3N403 448.17 449.22 F r O 7 N-N 28 N_ C22H28N40S 396.20 397.22 0 1 s N-N 29 . C25H25CIN403S2 528.11 530.08 .N 30 C25H25CIN402 448.17 449.22 c -- N 53 31 C25H38N40 410.31 411.32 N--N 32 C23H28N402 392.22 393.24 N -N 33 N- C24H30N402 406.24 407.25 N- N 34N- C23H28N403S 440.19 441.20 N-N 35 _C26H29BrN60 520.16 521.16 149 ~' N -N 36 ~N- C25H27N502 429.22 430.23 37 C24H27BrN602 510.14 512.13 N-N 38 N C26H32N403 448.25 449.26 N-N 39 _C25H23F3N402 468.18 469.21
F
54 40 N C25H25N504 459.19 460.21 0.0C N N 41 C25H22CIF3N402 502.14 503.18 N-N 42 \N C25H30N403 434.23 435.24 ~0 43 C25H29N50S 447.21 448.21 NO N-N 44 N- C28H28N60 464.23 465.27 "--' N N 45 N_ C32H33N50S 535.24 536.25 - -- N-N 46 N C26H26N40 410.21 411.23 - N N-N 47 \N C28H30N40 438.24 439.27
N
Nr -' 48 C29H29N50 463.24 464.26 N
N-N
55 49N C25H30N402 418.24 419.24 N--N 50 \ C25H29N502 431.23 432.25 51 C24H30N40S 422.21 423.23 52 C24H29FN40 408.23 409.24 -- N 53 \N -- C22H26N402S 410.18 411.21 IIN--N 54 C25H30N40 402.24 403.26 NN 55 N--C28H30N402 454.24 455.25 56 _ C28H29N502 467.23 468.27 57 _ C23H27CIN4OS 442.16 443.17 N-N 58 \N- C26H26N403S 474.17 475.19 56 59 N C28H29N502 467.27 468.27 N-N 60 \ C24H26N60 414.22 415.23 N ~ N-N 61 N-- C24H25N50S 431.18 432.19 N-N 62 _ C27H25N50 435.21 436.23 N-N 63 C26H24N402 424.19 425.22 N-N 64 C24H23FN40S 434.16 435.19 F N-N 65 . C25H29FN402 436.23 437.26 66 \N- C27H27FN40 442.22 443.24 N 67 _ C27H31FN402 462.24 464.36 F N--N 68 C25H25CIN403 464.16 465.18
N
CIJ
57 69 N_ C24H24N403 416.19 417.20 0 D' N-N 70 N- C23H23F3N402 444.18 445.20 SN F N-N 71 N_ C23H23N50 385.19 386.22 N. N-N 72 C'"' C28H29FN40 456.23 457.25
<>.,JK.,N
73 N_ C26H29FN402 448.23 449.24 o N-N 74 C22H23F3N40S 448.15 449.16 N-N 75 C24H24CIN50S 465.14 466.15 J/ 76 \ _- C25H25C1N402 448.17 449,20 N-N 77 C24H36N40 396.29 397.31 -r N-N 78 N.. C29H30N402 466.24 467.27 N',.0<N 58 79 '.. C25H32N403 436.25 437.27 80 \ C24H25CN60 448.18 449.21 0 NN cN 81 N- C27H25F3N402 494.19 495.22 F/ -N-N 82 N C26H25FN40 428.20 429.23 83 F NsC23H25F3N40 430.20 431.20 N 0 N N 83 4 N C25H25F3N402 430.0 43.17 N N N N-N 86 N C24H22CIN504 479.14 480.15
N
87 __- C27H28N40 424.23 425.24 88 \N C25H32N402 420.25 421.26
N-N
59 89 \N_ C27H28N40 424.23 425.24 90 C23H25F3N402 446.19 447.19 F F."/ N-N 91 \N- C23H25N50S 419.18 420.11 N N-N 92 \N_ C26H28N402 428.22 429.24 C N-N Example 93 Dimethyl-( 1-{4-[5-(4-phenoxybutyl)[ 1,3,4]oxadiazol-2-yl]phenyl pyrrolidin-3-yl)amine 5 N, O O N N-N PyBOP (25.2 mg) was added to a mixture of 4-phenoxybutanohydrazide (10 mg), 4-(3 dimethylaminopyrrolidin-l -yl)benzoic acid (12.1 mg), HOAt (6.6 mg), triethylamine (13.5 10 [l) and DMF (0.15 ml) at 0 0 C. The mixture was stirred at 0 0 C for 10 min and then at room temperature for 3 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo. 15 The residue was then taken up in THF (0.4 ml), and EDC (6.1 mg) and triethylamine (5.5 [l) were added, and the mixture was stirred at 50'C for 16 h. Ethyl acetate and water were 60 then added to the reaction solution. The organic phase subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was 5 obtained in this way; MS (ESI): 407.15 (M+H+). 4-Phenoxybutanohydrazide A mixture of phenol (100 mg), ethyl 5-bromovalerate (222.2 mg), cesium carbonate (693 mg) and DMF (1.6 ml) was stirred at room temperature for 12 h. Ethyl acetate and water 10 were then added to the reaction solution, and the aqueous phase was adjusted to pH 6 with 2N HCI solution. The aqueous phase extracted twice more with ethyl acetate. The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The product obtained in this way was taken up in abs. ethanol (0.5 ml), 37.3 tl of 15 hydrazine hydrate were added, and the mixture was heated under reflux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was neutralized with 2N HCI solution. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative 20 HPLC. The product with the molecular weight of 208.11 (C 11 H16CIN202) was obtained in this way; MS (ESI): 209.1 (M+H+). 4-(3-Dimethylaminopyrrolidin- 1 -yl)benzoic acid A IM sodium cyanoborohydride solution (1.32 ml) was added to a mixture of methyl 4 25 (3-aminopyrrolidin- I -yl)benzoate (300 mg), acetic acid (81 p1l), formaldehyde (0.113 ml) and THF (3 ml). The reaction was stirred at room temperature for 1 h, then the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate/water. The organic phase was washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. 30 The product obtained in this way was dissolved in a THF/water mixture (1:1) (3.1 ml), and potassium hydroxide (66.2 mg) was added. The reaction was heated at 70'C for 4 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was acidified with 2N HCI solution. The aqueous phase was extracted twice with ethyl acetate.
61 The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The product with the molecular weight of 234.17 (C13H 18N202) was obtained in this way; MS (ESI): 235.10 (M+H+). 5 Methyl 4-(3-aminopyrrolidin- I -yl)benzoate A mixture of 3-(tert-butoxycarbonylamino)pyrrolidine (I g), methyl 4-fluorobenzoate (0.83 ml), cesium carbonate (1.7 g) and DMF (10 ml) was heated at 100'C for 12 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice with water and dried over sodium sulfate, and the solvent was removed in 10 vacuo. The product obtained in this way was dissolved in methylene chloride (12 ml), trifluoroacetic acid (6 ml) was added, and the mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, and the residue was purified by preparative HPLC. The product with the molecular weight of 220.12 (CI2H16N202) was obtained in 15 this way; MS (ESI): 221.10 (M+H+). Example 94 (I - 4-[5-(4-Butoxyphenyl)-[l ,3,4]thiadiazol-2-yl]phenyl} pyrrolidin-3-yl)dimethylamine ON S N N-N 20 A mixture of N'-(4-butoxybenzoyl)-4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), Lawesson's reagent (191 mg) and toluene (5 ml) was boiled under reflux for 4 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 422.60 (C24H30N40S) was obtained in this way; 25 MS (ESI): 423 (M+H+). N'-(4-Butoxybenzoyl)-4-(3-dimethylaminopyrrolidin- 1 -yl)benzohydrazide A mixture of 4-butoxybenzoic acid (156 mg) and DMF (10 ml) was mixed with TOTU (264 mg) and N,N-diisopropylethylamine (104 mg). After 10 minutes, 4-(3- 62 dimethylaminopyrrolidin-1-yl)benzohydrazide (200 mg) was added. After one hour, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated. The product with the molecular weight of 424.55 (C24H32N403) was obtained in this way; MS (ESI): 5 425 (M+H+). Example 95 ((R)-3-{4-[5-(4-Chlorophenoxymethyl)[l ,2,4]oxadiazol-3-yl]phenyl }cyclopentyl) methylamine 10 CL O--N PyBOP (558 mg), HOAt (146 mg) and triethylamine (0.299 ml) were added to a mixture of tert-butyl {(R)-1-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3-y } methylcarbamate 15 (358.5 mg), (4-chlorophenoxy)acetic acid (200 mg) and 3 ml of DMF at 0 0 C, and the reaction mixture was stirred at this temperature for 10 min. It was then stirred at room temperature for 2 h and ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the 20 solvent was removed in vacuo. The residue was then taken up in 10 ml of THF, and EDC (160 mg) and triethylamine (0.144 ml) were added, and the mixture was stirred at 50*C for 16 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and 25 water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The crude product was taken up in methylene chloride (7.2 ml), and trifluoroacetic acid (1.8 ml) was added. The reaction was stirred at room temperature for 5 h and then the solvent was removed in vacuo. The residue was purified by preparative HPLC. The 63 product with the molecular weight of 384.14 (C20H21C1N402) was obtained in this way; MS(ESI): 385.26 (M+H+). (4-Chlorophenoxy)acetic acid 5 A mixture of 4-chlorophenol (500 mg), methyl bromoacetate (0.368 ml), cesium carbonate (1.9 g) and 5 ml of acetone was stirred at room temperature for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The crude product was dissolved in a 1:1 THF/water mixture (10 ml), and potassium 10 hydroxide (417 mg) was added. The reaction was stirred at room temperature for 12 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was adjusted to pH 2 and extracted several times with ethyl acetate. The combined organic phases were washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The product with the molecular weight of 186.6 15 (C8H7C0O3) was obtained in this way; MS (ESI): 227.0 (M+CH3CN). {(R)-I-[4-(N-Hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl}methylcarbamic acid tert-butyl ester Sodium hydride (253.4 mg) was added in portions to a solution of tert-butyl [(R)-1-(4 20 cyanophenyl)pyrrolidin-3-yl]carbamate (1.06 g) in 12 ml of DMF at 0 0 C. After removal of the ice bath, methyl iodide (0.498 ml) was added dropwise to the reaction solution, which was stirred at room temperature for 4 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. 25 The crude product was dissolved in abs. ethanol (12 ml), and hydroxylamine (0.687 ml) was added. The reaction solution was heated under reflux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 334.42 30 (CI7H26N403) was obtained in this way; MS (EST): 335.20 (M+H+). [(R)- I -(4-Cyanophenyl)pyrrolidin-3-yl]carbamic acid 64 A mixture of (3R)-(+)-(tert-butoxycarbonylaminopyrrolidine (1.0 g), p-fluorobenzonitrile (650 mg), cesium carbonate (1.75 g) and 5 ml of DMF was stirred at 50'C for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was 5 removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 287.36 (C16H2lN302) was obtained in this way; MS (ESI): 288.20 (M+H+). Example 96 10 ((R)- 1-{4-[5-(4-Chlorobenzyloxymethyl)[ l,2,4]oxadiazol-3-yl]phenyl Ipyrrolidin 3-yl)methylamine N N N S --N 15 A solution of (4-chlorobenzyloxy)acetic acid (70 mg) in thionyl chloride (1 ml) was stirred at room temperature for I h, and then toluene was added and the solvent was stripped off in vacuo. This procedure was repeated twice more. The acid chloride was then taken up in methylene chloride (1.4 ml), {(R)-i-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3 yl}methylcarbamic acid tert-butyl ester (116.7 mg), triethylamine (0.05 ml) were added, 20 and the mixture was stirred at room temperature for 12 h. The volatile components were removed in vacuo, and the residue was taken up in ethyl acetate/water. The organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 398.15 (C21 H23CN402) was obtained in this way; MS (ESI): 399.41 (M+H+). 25 (4-Chlorobenzyloxy)acetic acid was prepared in analogy to (4-chlorophenoxy)acetic acid using 4-chlorobenzyl bromide as precursor. The product with the molecular weight of 200.62 (C9H9Cl03) was obtained in this way; MS (ESI): 222.95 (M+Na-H). 30 Example 97 65 4-Chloro-N- { 3-[4-(3-dimethylaminopyrrolidin- 1 -yl)phenyl]l 1,2,4]oxadiazol 5-ylmethyl }benzamide 0 F N -N 5 Method C TOTU (51.4 mg) and N,N-diisopropylethylamine (0.05 ml) were added to a mixture of {1 (4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl dimethylamine (75.3 mg), 4-chlorobenzoic acid (23.5 mg) and DMF (0.96 ml), and the solution was stirred at room 10 temperature for 12 h. The crude product was purified by preparative HPLC (RP) and then purified again by chromatography on silica gel (dichloromethane/MeOH/AcOH/H 2 0 = 90/10/1/1). The product with the molecular weight of 425.16 (C22H24C1N502) was obtained in this way; MS (ESI): 426.17 (M+H). 15 { 1 -[4-(5-Aminomethyl[ ,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl dimethylamine PyBOP (546.4 mg), HOAt (136.1 mg) and triethylamine (0.279 ml) were added to a mixture of 4-(3-dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine (248.3 mg), tert butoxycarbonylaminoacetic acid (175.2 mg) and DMF (2.8 ml) at 0 0 C and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 2 20 h and then ethyl acetate and water were added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the solvent removed in vacuo. The residue was then taken up in 6.2 ml of THF, and EDC (105 mg) and triethylamine (0.09 ml) were added, and the mixture was stirred at 50'C for 16 h. Ethyl 25 acetate and water were then added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo. The crude product was taken up in methylene chloride (9.6 ml), and trifluoroacetic acid (2.3 ml) was added. The reaction was stirred at room temperature for 5 h and then the 30 solvent was removed in vacuo. The residue was purified by preparative HPLC. The 66 product with the molecular weight of 287.37 (CI5H21N50) was obtained in this way; MS (ESI): 288.05 (M+H+). 4-(3-Dimethylaminopyrrolidin- 1 -yl)-N-hydroxybenzamidine 5 A mixture of 3-(dimethylamino)pyrrolidine (1. 1 g), p-fluorobenzonitrile (1.2 g), potassium carbonate (2.8 g) and acetonitrile (15 ml) was stirred at 80'C for 12 h. The reaction solution was then filtered, and the precipitate was washed with acetonitrile, the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate. The ethyl acetate phase was washed twice with water and then dried over sodium sulfate, and the solvent 10 was removed in vacuo. The product obtained in this way was dissolved in abs. ethanol (48.7 ml), and hydroxylamine (1.4 ml) was added to the solution. The reaction mixture was heated under reflux for 12 h. The precipitate obtained after cooling the reaction solution was filtered off and washed with a little ethanol. 15 The product with the molecular weight of 248.33 (C13H20N40) was obtained in this way; MS (ESI): 249.15 (M+H+). Examples 98-110 in table 2 were synthesized by method C.
67 Ex. [Structurme - Mecular formula 1MW rMW ______________________caic. Lmeasired 98 C2H26C1N502 1439.18 440.19 99 -. i 2CI50 455.17 461 4100 9C22H23C!FN502 T443,15 444.21 I ., C22H25N502 1391.20 392.25 lb '+t22H23(cFN502 1443.15 444.21 103 /C 22FI24FN502 1409.19 410.22 104 C21H24N602 -- 392.20 393,24 '105 ,vC21 F23CIN602 426.16 427.19 06 - C21H24N602 39.0393.25 [17C21 H23CIN602 426.16 427.20 108 r\ [C21H24N602 392.20 393.26 ________ _____________"T________________________________________ __________ 109 >. 21H31N502 385.25 386.27 110 ,*-. C3H33N502 41.26 412.30 Example 11I1 [ 1-(4-f 5-[(4-Chlorobenzylamino)methyl][ [1,2,4]oxadiazol-3-yi } phenyl)pyrrolidin-3-ylI 5 dimethylamine 68 N N N N\ Cr Method D 5 Polymer-bound sodium cyanoborohydride (5 eq) was added to a mixture of (1-[4-(5 aminomethyl[1,2,4]oxadiazol-3-yl)phenyllpyrrolidin-3-yl} dimethylamine (40.1 mg), 4-chlorobenzaldehyde (42.2 mg), acetic acid (17.2 Rl), triethylamine (27.9 [LI) and THF (I ml), and the reaction mixture was stirred at room temperature for 12 h. The polymer bound reagent was filtered off and the solvent was removed in vacuo. The residue was 10 purified by preparative HPLC. The product with the molecular weight of 411.18 (C22H26C1N50) was obtained in this way; MS (ESI): 412.23 (M+H+). Example 112 [l-(4-{5-[(4-Methoxybenzylamino)methyl][1,2,4]oxadiazol-3-ylphenyl)pyrrolidin 15 3-y]dimethylamine / \ NN N ON {1-[4-(5-aminomethyl[ 1,2,4]oxadiazol-3-yl)phenyl)pyrrolidin-3-yl dimethylamine was 20 reacted with p-anisaldehyde by method D. The product with the molecular weight of 407.23 (C23H29N502) was obtained in this way; MS (ESI): 408.30 (M+H+). Example 113 (1-{4-[5-(4-Fluorobenzyloxymethyl)[l,2,4]oxadiazol-3-yl]phenyl}pyrrolidin 25 3-yl)dimethylamine 69 N N N 0-N F' 4-Fluorobenzyl bromide (18.9 mg) and potassium carbonate (27.6 mg) were added to a mixture of {3-[4-(3-dimethylaminopyrrolidin- 1-yl)phenyl][1,2,4]oxadiazol-5-yl) methanol 5 (28.8 mg) and DMF (0.3 ml). The reaction mixture was stirred at 60'C for 3 h, filtered and purified by preparative HPLC. The product with the molecular weight of 396.20 (C22H25FN402) was obtained in this way; MS (ESI): 397.27 (M+H+). (3-[4-(3-Dimethylaminopyrrolidin- I -yl)phenyl][I1,2,4]oxadiazol-5-yl) methanol PyBOP (546.4 mg), HOAt (136.1 mg) and triethylamine (0.139 ml) were added to a 10 mixture of 4-(3-dimethylaminopyrrolidin-I-yI)-N-hydroxybenzamidine (248.3 mg), benzyloxyacetic acid (0.143 ml) and DMF (3.0 ml) at 0 0 C, and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 1 h, and then ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium 15 bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was then taken up in 3 ml of THF, and EDC (170.8 mg) and triethylamine (0. 139 ml) were added, and the mixture was stirred at 80'C for 16 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice 20 each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was dissolved in methylene chloride (4.4 ml), and the solution was cooled to -78'C. At this temperature, a IM boron trichloride solution (3 ml) was added. The reaction 25 was allowed to warm to room temperature overnight, and then ethyl acetate and water were added. The product with the molecular weight of 288.2 (C15H20N402) was obtained in this way; MS (ESI): 289.2 (M+H+).
70 The following examples could be synthesized analogously: A ~T Y NN - US N-N NNNN N-N-N C \ N N N-N 1s'' _ IO
N-N
71 H AA I. N-N AB 0 O'O K #~ 'AC N I -N NNN 0 ~~~AD kNNN <2 N N-N Mr-7 ,AE N ~N-4 t4~> N-N N /AF N s y- N' -N N--N 0 NAG N N-N i N-N 0 Al 0 R SN 1

Claims (10)

  1. 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 ) alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo 15 groups; R3 H, (CI-C 6 )-alkyl; R4, R5 independently of one another H, (CI-C 6 )-alkyl, OH, 0-(CI-C)-alkyl, 20 O-CO(CI-C 6 )-alkyl, S-(CI-C 6 )-alkyl; R6, R7, R8, R9 independently of one another H, (CI-Cs)-alkyl, or 25 R6 and R7, R8 and R9 independently of one another optionally oxo; n, m independently of one another 0, 1, 2; 30 A, B, D, G independently of one another N, C(R38); R38 H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O-(Cf-C 6 )-alkyl, 0-(C 1 C 4 )-alkoxy-(Ci-C 4 )-alkyl, S-(Ci-C 6 )-alkyl, (CI-C 6 )-alkyl, (C 2 -C 6 )- 75 alkenyl, (C 3 -C 8 )-cycloalkyl, 0-(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 ) cycloalkenyl, O-(C 3 -Cs)-cycloalkenyl, (C 2 -C 6 )-alkynyl, (CO-C 8 ) alkylene-aryl, O-(Co-Cs)-alkylene-aryl, S-aryl, N(R39)(R40), SO 2 CH 3 , COOH, COO-(CI-C 6 )-alkyl, CON(R4 1)(R42), 5 N(R43)CO(R44), N(R45)SO 2 (R46), CO(R47), -(CR48R49)x O(R50); R39, R40, R41, R42, R43, R45 independently of one another H, (CI-Cs)-alkyl; 10 or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms 15 from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur; R44, R46, R47 independently of one another H, (CI-Cs)-alkyl, aryl; 20 R48, R49 independently of one another H, (CI-Cs)-alkyl; R50 H, (Ci-C 6 )-alkyl; x 1, 2, 3, 4; 25 Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR51 R52)y- in which one or more (CR5 I R52)- groups may be replaced by Y to result in a chemically 30 reasonable radical, C=C, C=C,; Y 0, S, N(R53), CO, SO, SO 2 ; 76 R51, R52 independently of one another H, (CI-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings; 5 y 1,2,3,4,5,6; R53 H, (CI-Cs)-alkyl; E 3-14 membered bivalent carbo- or heterocyclic ring structure having 10 0-4 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O-(CI-C 6 )-alkyl, O-(C 1 -C 4 )-alkoxy-(Ci-C 4 )-alkyl, S (C 1 -C 6 )-alkyl, (CI-C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, 0 (C 3 -Cs)-cycloalkyl, (C 2 -C 6 )-alkynyl, (Co-C 8 )-alkylene-aryl, 0-(Co 15 Cs)-alkylene-aryl, S-aryl, N(R54)(R55), S0 2 -CH 3 , COOH, COO (C I-C 6 )-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SO 2 (R61), CO(R62) and be mono- or bicyclic; R54,R55,R56,R57,R58,R60 20 independently of one another H, (CI-Cs)-alkyl; R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart 25 from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 )-alkyl, oxygen and sulfur; R59, R61, R62 independently of one another H, (Ci-Cs)-alkyl, aryl; 30 K a bond, a group of the formula -(CR63R64),- in which one or more (CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C=C, C=C; 77 Z 0, S, N(R65), CO, SO, SO 2 ; R63, R64 independently of one another H, (Cl-Cs)-alkyl, hydroxy, (CI-C 6 ) 5 alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings; z 1,2,3,4,5,6; 10 R65 H, (C 1 -Cs)-alkyl; R II H, (CI-Cs)-alkyl, (C-C 4 )-alkoxy-(C-C 4 )-alkyl, (C 3 -Cs)-alkenyl, (C 3 -Cs)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of 15 oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C 6 )-alkyl, 0-(C-C 8 ) alkyl, (C-C 4 )-alkoxy-(C-C 4 )-alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(CI-C4)-alkyl, COO(R69), N(R70)CO(C-C 6 )-alkyl, N(R71)(R72) or SO 2 CH 3 ; 20 R66, R67, R68, R69, R70, R7 1, R72 independently of one another H, (CI-C)-alkyl; or R67 and R68, R71 and R72 25 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 )-alkyl, oxygen and sulfur; or 30 the N-oxides thereof and the physiologically tolerated salts thereof. 2. A compound of the formula I as claimed in claim 1, 78 in which the meanings are RI, R2 independently of one another H, (Ci-Cs)-alkyl, -(CR13RI4) 0 -R12, (CI-C 4 )-alkoxy-(Ci-C 4 )-alkyl, (C 3 -Cs)-alkenyl, (C 3 -Cs)-alkynyl, CO 5 (CI-Cg)-alkyl, -CO-(CH 2 )o-R12, CO(C(R I 5)(R I 6))qN(R 17)(R 18), CO(C(R I 9)(R20)),O(R2 1); or R I and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional 10 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF 3 , NO 2 , CN, (CI-C 6 )-alkyl, 0-(CI-Cs)-alkyl, (Ci-C 4 ) alkoxy-(CI-C 4 )-alkyl, hydroxy-(CI-C 4 )-alkyl, (Co-Cg)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), 15 N(R26)CO(CI-C 6 )-alkyl or N(R27)(R28). R 12 OH, 0-(CI-C)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and 20 S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O-(CO-C 6 )-alkyl, (CI-C4)-alkoxy-(C-C 4 )-alkyl, S-(CI-C)-alkyl, (CI-C)-alkyl, (C 2 C)-alkenyl, (C 3 -Cs)-cycloalkyl, (C 2 -C)-alkynyl, O-(Co-C 8 ) alkylene-aryl, (CO-C 8 )-alkylene-aryl, N(R34)(R35), CO(CI-C 6 )-alkyl 25 and COO(R36); and R6, R7, R8, R9 independently of one another H, (Ci-Cg)-alkyl; 30 where the further radicals and groups in the compound of the formula I have the meanings stated in claim 1. 79 3. A compound of the formula I as claimed in claim 1, in which the meanings are 5 RI, R2 independently of one another H, (CI-Cs)-alkyl, -(CR13R14). -R12, (CI-C4)-alkoxy-(CI-C4)-alkyl, (C 3 -Cs)-alkenyl, CO-(CI-Cs)-alkyl, CO-(CH 2 )o -RI 2, CO(C(R I 5)(R 16))qN(R 17)(R 18), CO(C(Rl9)(R20)),O(R2l); or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, 10 bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (CI-C)-alkyl, O-(CI-C 4 ) alkyl, (CI-C4)-alkoxy-(Ci-C4)-alkyl, hydroxy-(CI-C 4 )-alkyl, (CO-C 2 ) 15 alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(CI-C 6 )-alkyl, N(R27)(R28) or SO 2 CH 3 ; o 0, 1,2,3,4,5,6; 20 q 1,2,3; s 0, 1,2,3,4; R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 25 independently of one another H, (Ci-C 6 )-alkyl; or R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart 30 from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur; 80 R12 OH, 0-(CI-C 6 )-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, 5 OH, CF 3 , CN, oxo, O-(CI-C 6 )-alkyl, (CI-C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (CI-C 6 )-alkyl, O-(Co-Cs)-alkylene-aryl, (Co-C 8 )-alkylene-aryl, N(R34)(R35), CO(CI-C)-alkyl, COO(R36), S(O),(R37); u 0, 1, 2; 10 R34, R35 independently of one another H, (Ci-Cg)-alkyl; or R34 and R35 15 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 ) alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups; 20 R36, R37 H, (Ci-C 8 )-alkyl; R13, R14 independently of one another H, (CI-Cs)-alkyl, hydroxy-(CI-C 4 ) alkyl, OH, (CI-C 4 )-alkoxy-(C 1 -C 4 )-alkyl; 25 R29, R30, R31 independently of one another H, (Ci-Cs)-alkyl; R3 H, (CI-C 6 )-alkyl; 30 R4, R5 independently of one another H, (CI-C 6 )-alkyl, OH, O-(Ci-C 6 )-alkyl, O-CO(CI-C)-alkyl, S-(CI-C 6 )-alkyl; 81 R6, R7, R8, R9 H; or R6 and R7, R8 and R9 5 independently of one another optionally oxo; n I m l or 2; 10 A, B, D, G independently of one another N, C(R38); or the groups A and B or D and G are in each case C(R38) and together 15 form an ortho-phenylene unit so that the overall result is a 1,4 bisubstituted naphthalene system; R38 H, F, Cl, Br, CF 3 , CN, O-(CI-C 6 )-alkyl, 0-(CI-C 4 )-alkoxy-(Ci-C 4 ) alkyl, S-(CI-C 6 )-alkyl, (CI-C 6 )-alkyl, (Co-C 8 )-alkylene-aryl, O-(Co Cs)-alkylene-aryl, N(R39)(R40), S0 2 -CH 3 , CON(R41)(R42), 20 N(R43)CO(R44), CO(R47), -(CR48R49).-O(R50); R39,R40,R41,R42,R43 independently of one another H, (CI-Cs)-alkyl; or 25 R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 )-alkyl, oxygen and sulfur; 30 R44, R47 independently of one another H, (CI-C 8 )-alkyl, aryl; R48,R49 H; 82 R50 H, (Ci-C 6 )-alkyl; x 1, 2; 5 Het five-membered aromatic heterocycle, preferably X'-Y' , X'-- A'-X' ,' X'A-X' N "N 10 Y-Z or Z'=Y in which A' is 0, S, NR73, X', Y' and Z' are independently of one another CR74 or N, and 15 R73, R74 are independently of one another H, (CI-C)-alkyl; X a bond, a group of the formula -(CR51 R52)y-, in which one or more (CR51 R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C; 20 R5 1, R52 independently of one another H, (Ci-C 4 )-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings; 25 Y 0, S, N(R53), CO; R53 H, (Ci-Cs)-alkyl; 83 E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O-(Ci-C 6 )-alkyl, 0-(CI-C 4 )-alkoxy-(Ci-C 4 )-alkyl, S-(Ci-C 6 ) 5 alkyl, (CI-C 6 )-alkyl, (C 2 -C)-alkenyl, O-(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 ) alkynyl, (Co-Cs)-alkylene-aryl, O-(Co-Cs)-alkylene-aryl, S-aryl, N(R54)(R55), S0 2 -CH 3 , N(R58)CO(R59), N(R60)SO 2 (R61), CO(R62) and be mono- or bicyclic; to R54, R55, R58, R60 independently of one another H, (CI-Cs)-alkyl; R59, R61, R62 independently of one another H, (CI-Cs)-alkyl, aryl; 15 K 0, a bond, CH 2 0, OCH 2 , S, SO, SO 2 , N(R80), N(R81)CO, CON(R82), (C(R83)(R84)),, CO, C=C, C=C, SCH 2 , SO 2 CH 2 ; v 1,2,3,4; 20 R80, R81, R82, R83, R84 independently of one another H, (CI-C 8 )-alkyl; RI 1 H, (Ci-C 8 )-alkyl, (CI-C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C3-C 8 )-alkenyl, (C 3 25 Cs)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, (Ci-C)-alkyl, O-(Ci-Cs)-alkyl, (Ci -C 4 )-alkoxy-(Ci -C 4 )-alkyl, hydroxy-(Ci -C 4 )-alkyl, (Co-C 8 ) 30 alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C 1 -C 6 )-alkyl, N(R7 1)(R72) or SO 2 CH 3 ; 84 R66,R67,R68,R69,R70,R7I,R72 independently of one another H, (CI-Cs)-alkyl; or R67 and R68, R71 and R72 5 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C-C 6 )-alkyl, oxygen and sulfur; or 10 the N-oxides thereof and the physiologically tolerated salts thereof. 4. A compound of the formula I as claimed in claim I or 3, in which the meanings are: 15 RI, R2 independently of one another H, (Ci-Cs)-alkyl, -(CR 13R I4) 0 -R12, (C-C 4 )-alkoxy-(C-C 4 )-alkyl, CO-(Cr-Cs)-alkyl, -CO-(CH 2 )o-R 12, CO(C(R 1 5)(R 1 6))qN(R I 7)(R 18), CO(C(R19)(R20)),O(R21); or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono 20 or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF 3 , (C 1 -C 6 )-alkyl, O-(CI-C 4 ) alkyl, (CI-C 4 )-alkoxy-(Ci-C4)-alkyl, (Co-C 2 )-alkylene-aryl, oxo, 25 CO(R22), hydroxy, N(R27)(R28) or SO 2 CH 3 ; preferably independently of one another H, (CI-Cs)-alkyl, (CRl3R14)o-R12, (C C4)-alkoxy-(CrC 4 )-alkyl, CO-(Ci-C 8 )-alkyl, -CO-(CH 2 )o-R12, CO(C(R15)(R16))qN(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 30 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system 85 may additionally be substituted by F, (CI-C 6 )-alkyl, (CI-C 4 )-alkoxy (Ci-C4)-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28); o 0, 1, 2, 3, 4; preferably 0, 1, 2, 3; 5 q l or 2; s 0, 1, 2, 3; preferably 0, 1, 2; R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R27, R28 10 independently of one another H, (CI-C 6 )-alkyl; or R 17 and R 18, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring selected from 15 pyrrolidine, piperidine, N-methylpiperazine and morpholine; R12 OH, O-(CI-C 6 )-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, 0 and S, and the 3-10 membered ring may comprise further substituents such 20 as F, Cl, Br, OH, CF 3 , CN, oxo, 0-(Ci-C 6 )-alkyl, (CI-C 4 )-alkoxy (C I-C4)-alkyl, (C I-C 6 )-alkyl, (Co-C 2 )-alkylene-aryl, N(R34)(R35), CO(CI-C 6 )-alkyl; preferably OH, O-(CI-C 6 )-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, 0 25 and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (CI-C 6 )-alkyl, CO(CI-C 6 )-alkyl; u 0 or 2; preferably 2; 30 R34, R35 independently of one another H, (Ci-C 8 )-alkyl; or R34 and R35 86 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 ) alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo 5 groups; R36, R37 H, (CI-Cs)-alkyl; Rl3, R14 independently of one another H, (CI-C 8 )-alkyl, hydroxy-(CI-C 4 ) 10 alkyl, OH, (CI-C4)-alkoxy-(CI-C 4 )-alkyl; R3 H; R4, R5 independently of one another H, (CI-C 6 )-alkyl, OH, O-(Ci-C 6 )-alkyl, 15 O-CO(CI-C 6 )-alkyl; preferably independently of one another H, OH, 0-(CI-C 6 )-alkyl, very particularly preferably H; R6, R7, R8, R9 H; 20 n m I; 25 A, B, D, G C(R38); R38 H, F, Cl, Br, CF 3 , CN, O-(Ci-C 6 )-alkyl, (CI-C 6 )-alkyl, S0 2 -CH 3 , CON(R4 1)(R42), N(R43)CO(R44), CO(R47), 30 -(CR48R49)x-O(R50); particularly preferably H, F, Cl, CF 3 , CN, (Ci-C 6 )-alkyl, -(CR48R49)x-O(R50); 87 R41, R42, R43 independently of one another H, (CI-Cs)-alkyl; or R39 and R40, R41 and R42 5 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Ci-C 6 )-alkyl, oxygen and sulfur; 10 R47 H, (Ci-Cs)-alkyl; R48, R49 H; R50 H, (CI-C 6 )-alkyl; 15 x 1; Het heteroaromatic group selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from 20 oxadiazoles, thiadiazoles, thiazoles and oxazoles; X a bond, CH 2 -CH 2 , CH 2 Y, YCH 2 , (R75)YCH 2 , CH 2 -NCO(R75), CH 2 CON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C=C; preferably a bond, CH 2 -CH 2 , C(R76)(R77), N(R75), CH 2 Y, 25 CH 2 Y(R75), CH 2 -NCO(R75), CH 2 -CON(R75); C=C; particularly preferably a bond, CH 2 -CH 2 , C(R76)(R77), C=C, (R75)YCH 2 , CH 2 NCO(R75); Y 0, S, N(R53); 30 R53 H, (Ci-Cs)-alkyl; R75, R76, R77, R78, R79 88 independently of one another H, (CI-Cs)-alkyl; E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 , CN, 5 OCF 3 , O-(CI-C 6 )-alkyl, S-(CI-C 6 )-alkyl, (Ci-C 6 )-alkyl, (C 2 -C 6 ) alkenyl, O-(Co-C 8 )-alkylene-aryl, S-aryl, N(R54)(R55), SO 2 -CH 3 , N(R58)CO(R59), CO(R62) and be mono- or bicyclic; preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, 0 and S, 10 which may optionally have substituents from the group of H, F, Cl, Br, OH, CF 3 , NO 2 , OCF 3 , O-(CI-C 6 )-alkyl, (CI-C 6 )-alkyl, (C 2 -C 6 ) alkenyl, N(R54)(R55), S0 2 -CH 3 , CO(R62), and which is particularly preferably monocyclic; e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, 15 cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, 1,2,3,6-tetrahydropyridine, 4,5 dihydroisoxazole, oxazole; R54, R55, R58 20 independently of one another H, (Ci-Cs)-alkyl; R59, R62 independently of one another H, (CI-C 8 )-alkyl; K 0, a bond, CH 2 0, OCH 2 , N(R80), N(R81)CO, CON(R82), 25 (C(R83)(R84)),, CO, C=C, SCH 2 ; preferably 0, a bond, CH 2 0, OCH 2 , CON(R82), (C(R83)(R84)),, CO, CaC; v 1, 2, 3; preferably 1,2; 30 R80, R81, R83, R84 independently of one another H, (CI-Cs)-alkyl; 89 RI1 (C 1 -Cs)-alkyl, (C-C4)-alkoxy-(C-C 4 )-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, 5 (C-C 6 )-alkyl, 0-(C-Cs)-alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C-C 6 )-alkyl, N(R71)(R72) or SO 2 CH 3 ; preferably (CI-C 8 )-alkyl, (C-C 4 )-alkoxy-(C-C 4 )-alkyl, a 3 to 10 membered mono- or bicyclic ring which may include 0 to 2 10 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 , CN, (C 1 -C 6 )-alkyl, O-(C-C 8 )-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(C-C 6 )-alkyl, or SO 2 CH 3 ; 15 R66, R67, R68, R70, R71, R72 independently of one another H, (CI-Cs)-alkyl; or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen 20 atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C-C 6 )-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof. 25 5. A compound of the formula I as claimed in any of claims 1 or 2 to 4, in which radicals RI, R2, RI 1, R38 and the groups X, E and K have the following meanings: 30 R I, R2 independently of one another H, (C 1 -C 8 )-alkyl, -(CRl3R14)o-R12, (C 1 -C 4 )-alkoxy-(C-C 4 )-alkyl, or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, 90 bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (CI-C 6 )-alkyl, O-(CI-C 4 )-alkyl, (CI 5 C 4 )-alkoxy-(C,-C4)-alkyl, hydroxy-(CI-C 4 )-alkyl, (Co-C 2 )-alkylene aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, N(R27)(R28) or SO 2 CH 3 ; preferably independently of one another H, (Ci-Cs)-alkyl, -(CR13R14)"-, R12, (CI-C 4 )-alkoxy-(C,-C 4 )-alkyl, or RI and R2 form together with the 10 nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (CI-C)-alkyl, O-(CI-C4)-alkyl, (CI-C4)-alkoxy-(Ci-C4)-alkyl, hydroxy 15 (CI-C 4 )-alkyl, (Co-C 2 )-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28); very particularly preferably independently of one another H, (CI-Cs)-alkyl, or RI and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to I additional heteroatoms selected 20 from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (CI-C)-alkyl; especially preferably independently of one another H, (Ci-C 8 )-alkyl; o 0, 1,2,3,4; 25 R22, R23, R24, R27, R28 independently of one another H, (Ci-C 6 )-alkyl; or R23 and R24, R27 and R28 30 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C 6 )-alkyl, oxygen and sulfur; 91 R 12 OH, O-(Ci-C 6 )-alkyl, CN 3-12 membered mono-, bi- or spirocyclic ring which may comprise I to 3 heteroatoms from the group of N, 0 and S, and the 3-12 membered ring may comprise further 5 substituents such as F, OH, CF 3 , CN, oxo, (CI-C 6 )-alkyl, (Co-C 2 ) alkylene-aryl, N(R34)(R35), COO(R36), CO(CI-C)-alkyl; R34, R35 independently of one another H, (CI-C 4 )-alkyl; I0 R36 H, (CI-C 6 )-alkyl, (Co-C 2 )-alkylene-aryl; R13, R14 independently of one another H, (CI-Cs)-alkyl, hydroxy-(CI-C 4 ) alkyl, OH, (CI-C 4 )-alkoxy-(C-C4)-alkyl; 15 R38 H, F, Cl, Br, CF 3 , CN, (CI-C 6 )-alkyl; X a bond, CH 2 CH 2 , C(R76)(R77), N(R75), C=C, (R75)YCH 2 , CH 2 NCO(R75), CH 2 CON(R75); 20 Y 0, S, N(R53), CO R75, R76, R77 independently of one another H, (CI-Cs)-alkyl; 25 R53 H, (Ci-C 8 )-alkyl; E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, 0 and S, which may optionally have substituents from the group of H, F, Cl, Br, CF 3 , OH, CN, 30 OCF 3 , 0-(Ci-C 6 )-alkyl, (Ci-C 6 )-alkyl, S0 2 -CH 3 , CO(R65); R65 H, (Ci-Cs)-alkyl; 92 K 0, a bond, CH 2 0, CH 2 , OCH 2 , S, S02, N(R80), N(R81)CO, CON(R82), (C(R83)(R84)),, CO, C-C, SCH 2 , SO 2 CH 2 ; preferably 0, a bond, CH 2 0, CH 2 , OCH 2 , N(R80), CaC; 5 v 1,2,3; R80,R81,R82,R83,R84 independently of one another H, (Ci-Cs)-alkyl; 10 RI 1 (Ci-Cs)-alkyl, (CI-C 4 )-alkoxy-(C-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF 3 . CN, (Ci-C 6 )-alkyl, O-(Ci-C 8 )-alkyl, oxo, CO(R66), hydroxy, 15 N(R70)CO(Ci-C)-alkyl, or SO 2 CH 3 ; R66, R70 independently of one another H, (CI-Cs)-alkyl; 20 the N-oxides thereof and the physiologically tolerated salts thereof.
  2. 6. A compound of the formula I as claimed in any of claims I to 5, in which 25 A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1, and for the case where the total number of nitrogen atoms is 1, particularly preferably A or B are N and very particularly preferably B is N. 30
  3. 7. A compound of the formula I as claimed in any of claims I to 6, 93 in which n is l and m is I or 2. 5 8. A medicament comprising one or more of the compounds as claimed in any of claims 1 to 7.
  4. 9. A medicament comprising one or more of the compounds as claimed in any of claims I to 7 and one or more anorectic active ingredients. 10
  5. 10. A compound of the formula I as claimed in any of claims 1 to 7 for use as medicament for the prophylaxis or treatment of obesity.
  6. 11. A compound of the formula I as claimed in any of claims 1 to 7 for use as 15 medicament for the prophylaxis or treatment of type H diabetes.
  7. 12. A compound of the formula I as claimed in any of claims 1 to 7 in combination with at least one further anorectic active ingredient for use as medicament for the prophylaxis or treatment of obesity. 20
  8. 13. A compound of the formula I as claimed in any of claims I to 7 in combination with at least one further anorectic active ingredient for use as medicament for the prophylaxis or treatment of type II diabetes. 25 14. A process for producing a medicament comprising one or more of the compounds of the formula I as claimed in any of claims I to 7, which comprises mixing the active ingredient with a pharmaceutically suitable carrier, and converting this mixture into a form suitable for administration. 30 15. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for producing a medicament for weight reduction in mammals. 94
  9. 16. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for producing a medicament for the prophylaxis or treatment of obesity.
  10. 17. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for 5 producing a medicament for the prophylaxis or treatment of type II diabetes.
AU2005206307A 2004-01-25 2005-01-25 Aryl substituted heterocycles, method for production and use thereof as medicaments Abandoned AU2005206307A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004003812A DE102004003812A1 (en) 2004-01-25 2004-01-25 Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals
DE102004003812.0 2004-01-25
PCT/EP2005/000699 WO2005070925A1 (en) 2004-01-25 2005-01-25 Aryl substituted heterocycles, method for production and use thereof as medicaments

Publications (1)

Publication Number Publication Date
AU2005206307A1 true AU2005206307A1 (en) 2005-08-04

Family

ID=34745116

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005206307A Abandoned AU2005206307A1 (en) 2004-01-25 2005-01-25 Aryl substituted heterocycles, method for production and use thereof as medicaments

Country Status (17)

Country Link
EP (1) EP1711494B1 (en)
JP (1) JP2007518770A (en)
KR (1) KR20060127917A (en)
CN (1) CN1934105A (en)
AR (1) AR047454A1 (en)
AT (1) ATE470666T1 (en)
AU (1) AU2005206307A1 (en)
BR (1) BRPI0507100A (en)
CA (1) CA2554138A1 (en)
DE (2) DE102004003812A1 (en)
DK (1) DK1711494T3 (en)
ES (1) ES2346889T3 (en)
IL (1) IL176916A0 (en)
PE (1) PE20050768A1 (en)
PT (1) PT1711494E (en)
TW (1) TW200536850A (en)
WO (1) WO2005070925A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341135B (en) 2005-12-21 2013-08-14 詹森药业有限公司 Substituted pyrazinone derivatives for the treatment of MCH-1 mediated diseases
EP2061767B1 (en) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008143649A2 (en) * 2006-12-04 2008-11-27 Dr. Reddy's Laboratories Limited Novel oxazolidinone compounds as antiinfective agents
MX2009005908A (en) 2006-12-05 2009-06-16 Janssen Pharmaceutica Nv Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases.
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
DE102007043281A1 (en) 2007-09-11 2009-05-28 Sebastian Dr. med. Chakrit Bhakdi Apparatus, materials and methods for high gradient magnetic separation of biological material
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
DE102008057364A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft New pyridyl or phenyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
DE102008057344A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituted aryl compounds and their use
DE102008057343A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft New phenyl or pyridyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
DE102009041241A1 (en) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia
DE102009041242A1 (en) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft New heterocyclically substituted aryl compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, ischemic cardiovascular diseases, heart attack, arrhythmia, stroke, and psoriasis
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
UA113501C2 (en) 2010-11-03 2017-02-10 PESTICIDE COMPOSITIONS AND RELATED METHODS
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
CA2852688C (en) 2011-10-26 2021-06-29 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
HK1209590A1 (en) 2012-04-27 2016-04-08 陶氏益农公司 Pesticidal compositions and processes related thereto
WO2015058028A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015058024A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004946A (en) 2013-10-17 2016-06-28 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds.
KR20160075565A (en) 2013-10-17 2016-06-29 다우 아그로사이언시즈 엘엘씨 Processes for the preparation of pesticidal compounds
EP3057431A4 (en) 2013-10-17 2017-04-05 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
JP2016536296A (en) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー Method for producing pest control compound
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016005317A (en) 2013-10-22 2016-08-12 Dow Agrosciences Llc Pesticidal compositions and related methods.
RU2016119368A (en) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи SYNERGETIC PESTICIDAL COMPOSITIONS AND RELATED WAYS
CN105658064A (en) 2013-10-22 2016-06-08 美国陶氏益农公司 Synergistic pesticidal compositions and related methods
RU2656391C2 (en) 2013-10-22 2018-06-05 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Pesticide compositions and related methods
AR098092A1 (en) 2013-10-22 2016-05-04 Dow Agrosciences Llc SYNERGIC PESTICIDE COMPOSITIONS AND RELATED METHODS
US9137998B2 (en) 2013-10-22 2015-09-22 Dow Agrosciences Llc Pesticidal compositions and related methods
US9282740B2 (en) 2013-10-22 2016-03-15 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016536307A (en) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー Agrochemical compositions and related methods
RU2016119576A (en) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи SYNERGETIC PESTICIDAL COMPOSITIONS AND RELATED WAYS
JP2016535733A (en) 2013-10-22 2016-11-17 ダウ アグロサイエンシィズ エルエルシー Synergistic pest control compositions and related methods
KR20160074640A (en) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 Pesticidal compositions and related methods
KR20160074634A (en) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 Synergistic pesticidal compositions and related methods
AR098099A1 (en) 2013-10-22 2016-05-04 Dow Agrosciences Llc SYNERGIC PESTICIDE COMPOSITIONS AND RELATED METHODS
RU2016119560A (en) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи SYNERGETIC PESTICIDE COMPOSITIONS AND WAYS RELATED TO THEM
MX2016005304A (en) 2013-10-22 2017-03-01 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods.
MX2016005306A (en) 2013-10-22 2016-08-12 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods.
TW201519786A (en) 2013-10-22 2015-06-01 陶氏農業科學公司 Insecticidal composition and related methods (1)
CN104072439B (en) * 2014-07-23 2015-11-04 张远强 The tetrazole acetophenone compound of halogen substiuted, Preparation Method And The Use
CN104072438B (en) * 2014-07-23 2015-10-14 张远强 Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use
CN104086502B (en) * 2014-07-23 2015-10-14 张远强 Halo tetrazole acetophenone compound, Preparation Method And The Use
CN104072436B (en) * 2014-07-23 2015-10-14 张远强 The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use
AR098110A1 (en) 2014-07-31 2016-05-04 Dow Agrosciences Llc PROCESS FOR THE PREPARATION OF 3- (3-CHLORINE-1H-PIRAZOL-1-IL) PIRIDINE
US9791067B2 (en) 2014-07-31 2017-10-17 Steffes Corporation Flare tip valve dampening
CN106470976A (en) 2014-07-31 2017-03-01 美国陶氏益农公司 The method of preparation 3 (3 chlorine 1H pyrazoles 1 base) pyridine
US9029555B1 (en) 2014-07-31 2015-05-12 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017002735A2 (en) 2014-08-19 2017-12-19 Dow Agrosciences Llc Process for the preparation of 3- (3-chloro-1h-pyrazol-1-yl) pyridine
KR20170058388A (en) 2014-09-12 2017-05-26 다우 아그로사이언시즈 엘엘씨 Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
TW201706265A (en) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 Lactams as inhibitors of ROCK
WO2017155869A1 (en) 2016-03-07 2017-09-14 X-Zell Inc. Compositions and methods for identifying rare cells
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN110139853B (en) 2016-12-29 2023-06-16 美国陶氏益农公司 Process for the preparation of pesticidal compounds
CN109651350B (en) * 2019-01-11 2022-05-24 贵州大学 A class of heterocyclic substituted 1,3,4-oxa(thi)adiazole compounds and preparation method and use thereof
KR20230152692A (en) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 GPR84 antagonists and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162235T3 (en) * 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv PIRIDAZINAMINS INHIBITORS OF ANGIOGENESIS.
AU2935200A (en) * 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
AU5251200A (en) * 1999-06-21 2001-01-09 Mitsubishi Pharma Corporation Novel imidazole derivatives
US6673923B2 (en) * 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
AU2003226927A1 (en) * 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
DE10306250A1 (en) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE502005009723D1 (en) 2010-07-22
TW200536850A (en) 2005-11-16
AR047454A1 (en) 2006-01-18
IL176916A0 (en) 2006-12-10
DK1711494T3 (en) 2010-10-11
EP1711494B1 (en) 2010-06-09
WO2005070925A1 (en) 2005-08-04
KR20060127917A (en) 2006-12-13
JP2007518770A (en) 2007-07-12
BRPI0507100A (en) 2007-06-19
PE20050768A1 (en) 2005-11-21
EP1711494A1 (en) 2006-10-18
CN1934105A (en) 2007-03-21
CA2554138A1 (en) 2005-08-04
DE102004003812A1 (en) 2005-08-11
PT1711494E (en) 2010-08-16
ES2346889T3 (en) 2010-10-21
ATE470666T1 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
AU2005206307A1 (en) Aryl substituted heterocycles, method for production and use thereof as medicaments
US7319108B2 (en) Aryl-substituted heterocycles, process for their preparation and their use as medicaments
ES2297758T3 (en) POLYCLINAL AMINES REPLACED WITH ARILO, PROCEDURE FOR PREPARATION AND USE AS MEDICINES.
EP1794159B1 (en) 7-azaindoles and their use as ppar agonists
IL198112A (en) 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
BRPI0707869A2 (en) azacyclyl substituted arylthienopyrimidinones, process for their preparation and their use as medicines
AU2005206308A1 (en) Substituted N-cyclohexyl imidazolinones having an MCH-modulatory effect
US7241787B2 (en) Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
MXPA06008338A (en) Aryl substituted heterocycles, method for production and use thereof as medicaments
HK1105965A (en) Apyl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application